

BIBLIOGRAPHY

COPYRIGHT © HARDIK GANDHI

BIBLIOGRAPHY

- Abboud FM (1974). Effects of sodium, angiotensin, and steroids on vascular reactivity in man. *Fed Proc*; 33: 143-149
- Abdullah MH, Satar MA, Abdullah NA, et al (2011). The effect of losartan and carvedilol on vasopressor responses to adrenergic agonists and angiotensin II in the systemic circulation of Sprague Dawley rats. *Autonomic and Autacoid Pharmacol*; 31: 13-20
- Adenekan OO, Tayo FM (1982). Analysis of the antagonism by prazosin of noradrenaline and phenylephrine induced contractions of the rat anococcygeus muscle. *J Autonomic Pharmacol*; 2: 241-246
- Ahmed FM, Shetty AS, Sridhar B (2010). RP-HPLC method for estimation of prazosin hydrochloride in pharmaceutical dosage form. *Int J Chem Sci*; 8: 1956-1964
- Akopononu BE, Mulrow PJ, Hoffman EA (1996). Secondary hypertension: evaluation and treatment. *Dis Mon*; 42: 609-722
- Alafeefy AM, Kadi AA, Al-Deeb OA, et al (2010). Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives. *Eur J Med Chem*; 45: 4947-4952
- Alderman MH, Cohen H, Madhavan S, et al (1999). Serum uric acid and cardiovascular events in successfully treated hypertensive patients. *Hypertension*; 34: 144-150
- Alessi DR, James SR, Downes CP, et al (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. *Curr Biol*; 7: 261-269
- Alexander RW, Brock TA, Gimbrone MA Jr, et al (1985). Angiotensin increases inositol trisphosphate and calcium in vascular smooth muscle. *Hypertension*; 7: 447-451
- Alexandrov A, Keffel S, Goepel M, et al (1999). Differential regulation of 46 and 54 kDa jun N-terminal kinases and p38 mitogen-activated protein kinase by human alpha(1A)-adrenoceptors expressed in Rat-1 cells. *Biochem Biophys Res Commun*; 261: 372-376
- Anand MP (2010). Epidemiology of hypertension in India. *Indian heart J*; 62: 388-393
- Antila S, Sundberg S, Lehtonen LA (2007). Clinical pharmacology of levosimendan. *Clin Pharmacokinet*; 46: 535-552

Bibliography

- Arnold AC, Okamoto LE, Gamboa A, et al (2013). Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. *Hypertension*; 61: 701-706
- Artunc F, Amann K, Nasir O, et al (2006). Blunted DOCA/high salt induced albuminuria and renal tubulointerstitial damage in gene-targeted mice lacking SGK1. *J Mol Med*; 84: 737-746
- Arunlakshana O, Schild HO (1959). Some quantitative uses of drug antagonists. *Br J Pharmacol Chemother*; 14: 48-58
- Attwell S, Roskelley C, Dedhar S (2000). The integrin-linked kinase (ILK) suppresses anoikis. *Oncogene*; 19: 3811-3815
- Auer KL, Spector MS, Tombes RM, et al (1998). α -Adrenergic inhibition of proliferation in HepG2 cells stably transfected with the α_{1B} -adrenergic receptor through a p42^{MAP kinase}/p21^{Cip1/WAF1}-dependent pathway. *FEBS Lett*; 436: 131-138
- Azizi M, Amar L, Menard J (2013). Aldosterone synthase inhibition in humans. *Nephrol Dial Transplant*; 28: 36-43
- Badyal DK, Lata H, Dadhich AP (2003). Animal models of hypertension and effect of drugs. *Ind J Pharmacol*; 35: 349-362
- Bae EH, Kim IJ, Ma SK, et al (2009). Altered regulation of renal sodium transporters and natriuretic peptide system in DOCA-salt hypertensive rats. *Reg Peptides*; 157: 76-83
- Bajda M, Guzior N, Ignasik M, et al (2011). Multi-target-directed ligands in Alzheimer's disease treatment. *Curr Med Chem*; 18: 4949-4975
- Ballou LM, Chattopadhyay M, Li Y, et al (2006). G_{α_q} binds to p110 α /p85 α phosphoinositide 3-kinase and displaces Ras. *Biochem J*; 394: 557-562
- Banno Y, Takuwa Y, Akao Y, et al (2001). Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3. *J Biol Chem*; 276: 35622-35628
- Barki-Harrington L, Luttrell LM, Rockman HA (2003). Dual inhibition of β -adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. *Circulation*; 108: 1611-1618
- Barrett-O'Keefe Z, Witman MA, McDaniel J (2013). Angiotensin II potentiates α -adrenergic vasoconstriction in the elderly. *Clin Sci*; 124: 413-422
- Baumgartner I, Isner JM (2000). Gene therapy for peripheral vascular disease. *Isr Med Assoc J*; 2: 27-32

Bibliography

- Bayascas JR, Alessi DR (2005). Regulation of Akt/PKB Ser473 phosphorylation. *Mol Cell*; 18: 143-152
- Beaudet A, Nouel D, Stroh T, et al (1998). Fluorescent ligands for studying neuropeptide receptors by confocal microscopy. *Brazilian J Med Biol Res*; 31: 1479-1489
- Beilin LJ (1988). Epitaph to essential hypertension: a preventable disorder of known aetiology. *J Hypertens*; 6: 85-94
- Bertagna X, Pivonello R, Fleseriu M, et al (2014). LCI699, a potent 11 β -hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. *J Clin Endocrinol Metab*; 99: 1375-1383
- Bidani AK, Griffin KA (2002). Long-term renal consequences of hypertension for normal and diseased kidneys. *Curr Opin Nephrol Hypertens*; 11: 73-80
- Bidani AK, Griffin KA (2004). Pathophysiology of Hypertensive Renal Damage: Implications for Therapy. *Hypertension*; 44: 595-601
- Biesen TV, Luttrell LM, Hawes BE (1996). Mitogenic signaling via G protein-coupled receptors. *Endocrine Rev*; 17: 639-669
- Bishopric NH, Simpson PC, Ordahl CP (1987). Induction of the skeletal alpha-actin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes. *J Clin Invest*; 80: 1194-1199
- Blasi ER, Rocha R, Rudolph AE, et al (2003). Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. *Kidney Int*; 63: 1791-1800
- Bolognesi ML, Bartolini M, Mancini F, et al (2010). Bis (7)-tacrine derivatives as multitarget-directed ligands: focus on anticholinesterase and anti-amyloid activities. *Chem Med Chem*; 5: 1215-1220
- Brook RD, Julius S (2000). Autonomic imbalance, hypertension, and cardiovascular risk. *Am J Hypertens*; 13: 112S-122S
- Brown MJ (2008). Aliskiren. *Circulation*; 118: 773-784
- Brown MJ (2009). Success and failure of vaccines against renin-angiotensin system components. *Nat Rev Cardiol*; 6: 639-647
- Budzyn K, Marley PD, Sobey CG (2005). Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase in vasoconstriction: effects of rho-kinase and hypertension. *J Pharmacol Exp Therap*; 313: 1248-1253

Bibliography

- Buijsman RC, Basten JE, van Dinther TG, et al (1999). Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action. *Bioorg Med Chem Lett*; 9: 2013-2018
- Burke SL, Head GA (2009). Cardiac and renal baroreflex control during stress in conscious renovascular hypertensive rabbits: effect of rilmenidine. *J Hypertens*; 27: 132-141
- Bylund DB (2007). Alpha- and beta-adrenergic receptors: Ahlquist's landmark hypothesis of a single mediator with two receptors. *Am J Physiol Endocrinol Metab*; 293: E1479-E1481
- Caetano ER, Zatz R, Saldanha SB, et al (2001). Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. *Hypertension*; 38: 171-176
- Cai H, Harrison DG (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res*; 87: 840-844
- Calhoun DA, Jones D, Textor S, et al (2008). Resistant hypertension: diagnosis, evaluation, and treatment. *Hypertension*; 51: 1403-1419
- Calhoun DA, Mutinga ML, Collins AS, et al (1993). Normotensive blacks have heightened sympathetic response to cold pressor test. *Hypertension*; 22: 801-805
- Callera GE, Touyz RM, Teixeira SA, et al (2003). ET_A receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. *Hypertension*; 42: 811-817
- Carey RM, Siragy HM (2003). Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. *Endocrine Rev*; 24: 261-271
- Carmeliet P, Moons L, Luttun A, et al (2001). Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med*; 7: 575-583
- Carnevale D, Vecchione C, Mascio G, et al (2012a). PI3K γ inhibition reduces blood pressure by a vasorelaxant. Akt/L-type calcium channel mechanism. *Cardiovasc Res*; 93: 200-209
- Carnevale D, Lembo G (2012b). PI3K γ in hypertension: a novel therapeutic target controlling vascular myogenic tone and target organ damage. *Cardiovasc Res*; 95: 403-408
- Carretero OA, Oparil S (2000). Essential Hypertension part I: definition and etiology. *Circulation*; 101: 329-335

Bibliography

- Cavalli A, Lattion AL, Hummler E, et al (1997). Decreased blood pressure response in mice deficient of the α_{1b} -adrenergic receptor. *PNAS USA*; 94: 11589 -11594
- Chaki S, Inagami T (1992). A newly found angiotensin II receptor subtype mediates cyclic GMP formation in differentiated Neuro-2A cells. *Eur J Pharmacol*; 225: 355-356
- Chang L, Karin M (2001). Mammalian MAP kinase signaling cascades. *Nature*; 410: 37-40
- Chapleau MW, Hajduczuk G, Abboud FM (1992). Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure. *Am J Physiol Reg Integr Comp Physiol*; 263: R103-R108
- Chen CL, Malaviya R, Navara C, et al (1999). Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. *Pharm Res*; 16: 117-122
- Chiolero A, Wurzner G, Burnier M (2001). Renal determinants of the salt sensitivity of blood pressure. *Nephrol Dial Transplant*; 16: 452-458
- Cho A, Courtman DW, Languille BL (1995). Apoptosis (programmed cell death) in arteries of the neonatal lamb. *Circ Res*; 76: 168-175
- Chobanian AV, Bakris GL, Black HR, et al (2003). The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA*; 289: 2560-2572
- Chopra S, Baby C, Jacob JJ (2011). Neuro-endocrine regulation of blood pressure. *Indian J Endocrinol Metab*; 15: S281-S288
- Chrysant SG (2003). The ALLHAT study: results and clinical implications. *Q J Med*; 96: 771-773
- Clarke NE, Turner AJ (2012). Angiotensin-Converting Enzyme 2: The First Decade. *Int J Hypertens*; 2012: 12 pages
- Clerk A, Farm Sh, Fuller SJ, et al (2001). Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1. *Mol Cell Biol*; 21: 1173-1184
- Constantino L, Barlocco D (2012). Designed multiple ligands: basic research vs clinical outcomes. *Curr Med Chem*; 19: 3353-3387
- Cotecchia S (2010). The α_1 -adrenergic receptors: diversity of signaling networks and regulation. *J Receptor Signal Transduc*; 30: 410-419

Bibliography

Cotecchia S, Rossier O, Fanelli F, et al (2000). The α_{1a} and α_{1b} -adrenergic receptor subtypes: molecular mechanisms of receptor activation and of drug action. *Pharmacochim Lib*; 31: 173-179

Cubeddu LX, Fuenmayor N, Varin F, et al (1987). Mechanism of the Vasodilatory Effect of Carvedilol in Normal Volunteers: A Comparison with Labetalol. *J Cardiovasc Pharmacol*; 10: 45-67

Cunha TS, José M, Moura CS, et al (2005). Vascular sensitivity to phenylephrine in rats submitted to anaerobic training and nandrolone treatment. *Hypertension*; 46: 1010-1015

Dahlof B, Devereaux RB, Kjeldsen SE, et al (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*; 359: 995-1003

Dale MM, Haylett DG (2009). *Pharmacology condensed* (1st edition; pp. 1-132); Elsevier, Canada.

Damron DS, Nadim HS, Hong SJ, et al (1998). Intracellular translocation of PKC isoforms in canine pulmonary artery smooth muscle cells by ANG II. *Am J Physiol Lung Cell Mol Physiol*; 274: L278-L288

Danziger RS (2001). Hypertension in an anthropological and evolutionary paradigm. *Hypertension*; 38: 19-22

Dasgupta K, Quinn RR, Zarnke KB, et al (2014). The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol*; 30: 485-501

Daugherty SL, Powers JD, Magid DJ, et al (2012). Incidence and prognosis of resistant hypertension in hypertensive patients. *Circulation*; 125: 1635-42

Davis JP, Chipperfield AR, Harper AA (1993). Accumulation of intracellular chloride by (Na-K-Cl) co-transport in rat arterial smooth muscle is enhanced in deoxycorticosterone acetate (DOCA)/salt hypertension. *J Mol Cell Cardiol*; 25: 233-237

Dawson Jr R, Liu S, Jung B, et al (2000). Effects of high salt diets and taurine on the development of hypertension in the stroke-prone spontaneously hypertensive rat. *Amino Acids*; 19: 643-665

de Gasparo M, Catt KJ, Inagami T, et al (2000). International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev*; 52: 415-472

Deng PY, Li YJ (2005). Calcitonin gene-related peptide and hypertension. *Peptides*; 26: 1676-1685

Bibliography

- Deng XF, Chemtob S, Varma DR (1996). Characterization of α_1D -adrenoceptor subtype in rat myocardium, aorta and other tissues. *Br J Pharmacol*; 119: 269-276
- Desir GV (2009). Regulation of blood pressure and cardiovascular function by renalase. *Kidney Int*; 76: 366-370
- Desir GV, Peixoto AJ (2014). Renalase in hypertension and kidney disease. *Nephrol Dial Transplant*; 29: 22-28
- Devi P, Rao M, Sigamani A, et al (2013). Prevalence, risk factors and awareness of hypertension in India: a systematic review. *J Hum Hypertens*; 27: 281-287
- Di Napoli M, Papa F (2003). NCX-4016 NicOx. *Curr Opin Invest Drugs*; 4: 1126-1139
- DiBona GF (1989a). Hypertension and renal alpha-adrenergic receptors. *FASEB J*; 3: 1993-1994
- DiBona GF (1989b). Sympathetic nervous system influences on the kidney: Role in hypertension. *Am J Hypertens*; 2: 119S-124S
- DiBona GF, Kopp UC (1997). Neural control of renal function. *Physiol Rev*; 77: 75-197
- Diez J, Laviades C, Mayor G, et al (1995). Increased Serum Concentrations of Procollagen Peptides in Essential Hypertension: Relation to Cardiac Alterations. *Circulation*; 91: 1450-1456
- Dinh DT, Fraugman AG, Johnston CI, et al (2001). Angiotensin receptors: distribution, signalling and function. *Clin Sci*; 100: 481-492
- Diviani D, Lattion AL, Larbi N, et al (1996). Effect of different G protein-coupled receptor kinases on phosphorylation and desensitization of the α_{1b} -adrenergic receptor. *J Biol Chem*; 271: 5049-5058
- Diviani D, Lattion AL, Cotecchia S (1997). Characterization of the phosphorylation sites involved in g protein-coupled receptor kinase- and protein kinase c-mediated desensitization of the α_{1b} -adrenergic receptor. *J Biol Chem*; 272: 28712-28719
- Donoghue M, Hsieh F, Baronas E, et al (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin (1-9). *Circ Res*; 87: E1-E9
- Dostal DE, Hunt RA, Kule CE, et al (1997). Molecular mechanisms of angiotensin ii in modulating cardiac function: intracardiac effects and signal transduction pathways. *J Mol Cell Cardiol*; 29: 2893-2902
- Downward J (2004). PI3-kinase, Akt and cell survival. *Semin Cell Dev Biol*; 15: 177-182

Bibliography

- Du Y, Qiu J, Nelson SH, et al (1997). Regulation of type 1 ANG II receptor in vascular tissue: Role of α_1 -adrenoreceptor. *Am J Physiol*; 273: R1224-R1229
- Dugourd C, Gervais M, Corvol P, et al (2003). Akt Is a Major Downstream Target of PI3-Kinase Involved in Angiotensin II-Induced Proliferation. *Hypertension*; 41: 882-890
- Eguchi S, Iwasaki H, Ueno H, et al (1999). Intracellular signaling of angiotensin ii-induced p70 S6 kinase phosphorylation at Ser⁴¹¹ in vascular smooth muscle cells. *J Biol Chem*; 274: 36843-36851
- Elliot WJ (2002). Is fixed combination therapy appropriate for initial hypertension treatment? *Curr Hypertens Rep*; 4: 278-285
- Emsley AM, Jeremy JY, Gomes GN, et al (1999). Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. *Br J Pharmacol*; 126: 1034-1040
- Esler M (2000). The sympathetic system and hypertension. *Am J Hypertens*; 13: 99S-105S
- Farviar RS, Crawford DC, Chobanian AV, et al (1995). Effect of angiotensin ii blockade on the fibroproliferative response to phenylephrine in the rat heart. *Hypertension*; 25: 809-813
- Faselis C, Doumas M, Papademetriou V (2011). Common secondary causes of resistant hypertension and rationale for treatment. *Int J Hypertens*; 236239
- Feig DI, Kang DH, Johnson RJ (2008). Uric acid and cardiovascular risk. *N Engl J Med*; 359: 1811-1821
- Feihl F, Liaudet L, Waeber B, et al (2006). Hypertension: A disease of microcirculation? *Hypertension*; 48: 1012-1017
- Fiebeler A, Nussberger J, Shagdarsuren E, et al (2005). Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. *Circulation*; 111: 3087-3094
- Firth AL, Remillard CV, Yuan JX (2007). TRP channels in hypertension. *Biochim Biophys Acta*; 1772: 895-906
- Floyd DM, Sills MA (2007). Pre-clinical development of PS433540, a dual-acting receptor antagonist (DARA) of the angiotensin and endothelin receptors. *J Clin Hypertens (Greenwich)*; 9: A158
- Forstermann U, Munzel T (2006). Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace. *Circulation*; 113: 1708-1714

Bibliography

Fournier D, Luft FC, Bader M, et al (2012). Emergence and evolution of the renin-angiotensin-aldosterone system. *J Mol Med*; 90: 495-508

Francis PC, Ward VN, Gries, AA (1992). Subchronic toxicity study in Fischer 344 rats treated orally with EL-436 (Compound 193136) for 3 months followed by a 1-month reversibility period; Lilly Research Laboratories, Greenfield

Franklin SS (2005). Arterial stiffness and hypertension: a two-way street. *Hypertension*; 45: 349-351

Franse LV, Pahor M, Bari MD, et al (2000). Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). *J Hypertens*; 18: 1149-1154

Fukui T, Ishizaka N, Rajagopalan S, et al (1997). p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. *Circ Res*; 80: 45-51

Fyhrquist F, Metsarinne K, Tikkanen I (1995). Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. *J Hum Hypertens*; 9: S19-S24

Galis ZS, Muszynski M, Sukhova GK, et al (1994). Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. *Circ Res*; 75: 181-189

Garcia-Sainz JA, Romero-Avila MT, Hernandez RA, et al (1992). Species heterogeneity of hepatic α_1 -adrenoceptors: α_{1A} -, α_{1B} - and α_{1C} -subtypes. *Biochem Biophys Res Commun*; 186: 760-767

Garcia-Sainz JA (1993). α_1 -adrenergic action: Receptor subtypes, signal transduction and regulation. *Cell Signal*; 5: 539-547

Garcia-Sainz JA, Villalobos-Molina R (2004). The elusive α_{1D} -adrenoceptor: molecular and cellular characteristics and integrative roles. *Eur J Pharmacol*; 500: 113-120

Garcia-Sainz JA, Romero-Avila MT, Alcatra-Hernandez R (2011). Mechanisms involved in α_{1B} -adrenoceptor desensitization. *IUBMB Life*; 63: 811-815

Garovic VD, Textor SC (2005). Renovascular hypertension and ischemic nephropathy. *Circulation*; 112: 1362-1374

Gautam CS, Saha L (2008). Fixed dose drug combinations (FDCs): rational or irrational: a view point. *Br J Clin Pharmacol*; 65: 795-796

Geltz NR, Augustine JA (1998). The p85 and p110 subunits of phosphatidylinositol 3-kinase-alpha are substrates, in vitro, for a constitutively associated protein tyrosine kinase in platelets. *Blood*; 91: 930-939

Bibliography

- Giachini FR, Lima VV, Carneiro FS, et al (2011). Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats role of phosphodiesterase-I. *Hypertension*; 57: 655-663
- Glagov S, Weisenberg E, Zarins CK, et al (1987). Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med*; 316: 1371-1375
- Goldstein DS (1981). Plasma norepinephrine in essential hypertension. A study of the studies. *Hypertension*; 3: 48-52
- Goligorsky MS (2010). Microvascular rarefaction: The decline and fall of blood vessels. *Organogenesis*; 6: 1-10
- Gradman AH, Basile JN, Carter BL, et al (2011). Combination therapy in hypertension. *J Clin Hypertens*; 13: 146-154
- Gradman AH, Kad R (2008). Renin inhibition of hypertension. *J Am Coll Cardiol*; 51: 519-528
- Graham RM, Perez DM, Hwa J, et al (1996). α_1 -Adrenergic receptor subtypes: molecular structure, function, and signaling. *Circ Res*; 78: 737-749
- Grassi G, Seravalle G, Cattaneo BM, et al (1995). Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. *Circulation*; 92: 3206-3211
- Grassi G (1998). Role of the sympathetic nervous system in human hypertension. *J Hypertens*; 16: 1979-1987
- Grassi G (2001). Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. *J Hypertens*; 19: 1713-1716
- Griendling KK, Tsuda T, Berk BC, et al (1989). Angiotensin II stimulation of vascular smooth muscle cells: secondary signalling mechanisms. *Am J Hypertens*; 2: 659-665
- Griendling KK, Minieri CA, Ollerenshaw JD, et al (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ Res*; 74: 1141-1148
- Griendling KK, Lassegue B, Alexander RW (1996). Angiotensin receptors and their therapeutic implications. *Ann Rev Pharmacol Toxicol*; 36: 281-306
- Griendling KK, Ushio-Fukai M, Lassegue B, et al (1997). Angiotensin II signaling in vascular smooth muscle. *Hypertension*; 29: 366-370
- Griendling KK, Ushio-Fukai M (2000). Reactive oxygen species as mediators of angiotensin II signaling. *Reg Peptides*; 91: 21-27

Bibliography

- Griendling KK, Sorescu D, Ushio-Fukai M (2000). NAD(P)H oxidase: role in cardiovascular biology and disease. *Circ Res*; 86: 494-501
- Gude D (2012). How full is our antihypertensives pipeline? *J Pharmacol Pharmacother*; 3: 7-11
- Guimaraes S, Paiva MQ, Moura D (1998). Different receptors for angiotensin II at pre- and postjunctional level of the canine mesenteric and pulmonary arteries. *Br J Pharmacol*; 124: 1207-1212
- Gunther S, Gimbrone MA Jr, Alexander RW (1980). Regulation by angiotensin II of its receptors in resistance blood vessels. *Nature*; 287: 230-232
- Guo GB, Abboud FM (1984). Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. *Am J Physiol Heart Circ Physiol*; 246: H80-H89
- Gupta AK, Harshad S, Poulter NR (2010). Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*; 55: 399-407
- Gupta R (2004). Trends in hypertension epidemiology in India. *J Human Hypertens*; 18: 73-78
- Gupta V, Lipsitz LA (2007). Orthostatic hypotension in the elderly: diagnosis and treatment. *Am J Med*; 120: 841-847
- Guyenet P (2006). The sympathetic control of blood pressure. *Nat Rev Neurosci*; 7: 335-346
- Guyton AC, Hall JE (2006). Overview of the circulation: Medical physics of pressure flow and resistance. In: *Textbook of Medical Physiology* (11th Edn; pp. 161-170); Elsevier Publications, Philadelphia.
- Hadizadeh F, Imen SM, Esmaeili P, et al (2010). Synthesis and effects of novel dihydropyridines as dual calcium channel blocker and angiotensin antagonist on isolated rat aorta. *Iranian J Basic Med Sci*; 11: 43-56
- Hajjar I, Kotchen JM, Kotchen TA (2006). Hypertension: trends in prevalence, incidence, and control. *Annu Rev Public Health*; 27: 465-90
- Hall JE, Brands MW, Henegar JR (1999). Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. *J Am Soc Nephrol*; 10: S258-S265
- Hall RA (2004). Beta-adrenergic receptors and their interacting proteins. *Semin Cell Dev Biol*; 15: 281-288

Bibliography

- Hamet P, Richard L, Dam TV, et al (1995). Apoptosis in target organs of hypertension. *Hypertension*; 26: 642-648
- Harrison-Bernard LM (2009). The renal renin-angiotensin system. *Adv Physiol Edu*; 33: 270-274
- Hawrylyshyn KA, Michelotti GA, Coge F, et al (2004). Update on human α_1 -adrenoceptor subtype signaling and genomic organization. *Trends Pharmacol Sci*; 25: 449-455
- Heinisch S, Rocca JL (2004). Effect of mobile phase composition, pH and buffer type on the retention of ionizable compounds in reversed-phase liquid chromatography: application to method development. *J Chromatogr A*; 1048: 183-193
- Hennekens CH (2008). Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations. *Am J Cardiovasc Drugs*; 8: 155-160
- Higuchi S, Ohtsu H, Suzuki H, et al (2007). Angiotensin II signal transduction through the AT₁ receptor: novel insights into mechanisms and pathophysiology. *Clin Sci*; 112: 417-428
- Hill MA, Davis MJ, Meininger GA, et al (2006). Arteriolar myogenic signalling mechanisms: implications for local vascular function. *Clin Hemorheol Microcirc*; 34: 67-79
- Hosoda C, Koshimizu TA, Tanoue A, et al (2005). Two α_1 -adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. *Mol Pharmacol*; 67: 912-922
- Hrometz SL, Edelman SE, McCune DF, et al (1999). Expression of multiple α_1 -adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction. *J Pharmacol Exp Therap*; 290: 452-463
- Hu ZW, Shi XY, Lin RZ, et al (1999). α_1 -Adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase. *J Pharmacol Exp Therap*; 290: 28-37
- Huang Y, Noble NA, Zhang J (2007). Renin-stimulated TGF- β 1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. *Kidney Int*; 72: 45-52
- Huffman MD (2014). Fixed dose combinations of cardiovascular drugs. *Br Med J*; 348: g3480

Bibliography

- Hussain MB, Marshall I (1997). Characterization of α_1 -adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery. *Br J Pharmacol*; 122: 849-858
- Ibarra M, Terron JA, Lopez-Guerrero JJ (1997). Evidence for an age-dependent functional expression of alpha 1D-adrenoceptors in the rat vasculature. *Eur J Pharmacol*; 322: 221-224
- Ichihara A, Kaneshiro Y, Takemitsu T, et al (2005). Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. *J Am Soc Nephrol*; 17: 2493-2503
- Imayama I, Ichiki T, Inanaga K, et al (2006). Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. *Cardiovasc Res*; 72: 184-190
- Intengan HD, Schiffrin EL (1999). Collagen degradation is diminished in mesenteric arteries of spontaneously hypertensive rats after hypertension is established. *Hypertension*; 34: 329 [Abstract]
- Intengan HD, Schiffrin EL (2001). Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis. *Hypertension*; 38: 581-587
- Isaacson C, Milne FJ, Niekerk IV, et al (1991). The renal histopathology of essential malignant hypertension in black South Africans. *S Afr Med J*; 80: 173-176
- Ishizaka N, Griendling KK, Lassegue B, et al (1998). Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. *hypertension*; 32: 459-466
- Iwaki K, Nakashima M, Kishi M (1997). Cardiovascular pharmacological characteristics of S-2150: a novel dual blocker of calcium channels and α_1 -adrenoceptors. *Cardiovasc Drug Rev*; 15: 299-313
- Iwaki K, Sukhatme VP, Shubeita HE, et al (1990). Alpha- and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. *fos/jun* expression is associated with sarcomere assembly; *Egr-1* induction is primarily an alpha 1-mediated response. *J Biol Chem*; 265: 13809-13817
- Iwashima F, Yoshimoto T, Minami I, et al (2008). Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. *Endocrinology*; 149: 1009-1014
- Iyer A, Chan V, Brown L (2010). The DOCA-salt hypertensive rat as a model of cardiovascular oxidative and inflammatory stress. *Curr Cardiol Rev*; 6: 291
- Jaillon P (1980). Clinical pharmacokinetics of prazosin. *Clin Pharmacokinet*; 5: 365-376

Bibliography

Jain KS, Bariwal JB, Kathiravan MK, et al (2008). Recent advances in selective α_1 -drenoreceptor antagonists as antihypertensive agents. *Bioorg Med Chem*; 16: 4759-4800

James PA, Oparil S, Carter BL, et al (2014). Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*; 311: 507-520

Jandeleit-Dahm KA (2008). Dual ACE/NEP inhibitors – more than playing the ACE card. *Lancet*; 371: 821-827

Jennings GL (2013). Recent clinical trials of hypertension management. *Hypertension*; 62: 3-7

Jhund PS, Claggett B, Packer M, et al (2014). Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. *Eur J Heart Failure*; 16: 671-677

Jia Z, Aoyagi T, Yang T (2010). mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. *Hypertension*; 55: 539-546

Jiménez R, López-Sepúlveda R, Kadmiri M, et al (2007). Polyphenols restore endothelial function in DOCA-salt hypertension: role of endothelin-1 and NADPH oxidase. *Free Radical Biol Med*; 43: 462-473

Johnson RJ, Kang DH, Feig D, et al (2003); Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? *Hypertension*; 41: 1183-1190

Johnson RJ, Feig DI, Nakagawa T, et al (2008). Pathogenesis of essential hypertension: historical paradigms and modern insights. *J Hypertens*; 26: 381-391

Johnston CI (1995). Angiotensin receptor antagonists: focus on losartan. *Lancet*; 346: 1403-1407

Jones JD, Jackson SH, Agboton C, et al (2011). Azilsartan medoxomil (edarbi): the eighth angiotensin II receptor blocker. *Pharmacy Therap*; 36: 634

Jones LS, Miller G, Gauger LL, et al (1985). Regional distribution of rat brain alpha 1-adrenergic receptors: correlation between (125 I)-heat membrane binding and in vitro autoradiography. *Life Sci*; 36: 45-51

Kanaide H, Ichiki T, Nishimura J, et al (2003). Cellular mechanism of vasoconstriction induced by angiotensin II. *Circ Res*; 93: 1015-1017

Kaplan NM (2011). Systemic hypertension: Treatment. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (9th edn; pp. 46); Elsevier, Philadelphia.

- Katholi RE, Couri DM (2011). Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. *Int J Hypertens*; 2011; 10 pages
- Katso R, Okkenhaug K, Ahmadi K, et al (2001). Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. *Ann Rev Cell Dev Biol*; 17: 615-675
- Kearney PM, Whelton M, Reynolds K, et al (2004). Worldwide prevalence of hypertension: a systematic review. *J Hypertens*; 22: 11-19
- Kenakin T (2009). Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect. *ACS Chem Biol*; 4: 249-260
- Kenny BA, Chalmers DH, Philpott PC, et al (1995). Characterization of an α 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. *Br J Pharmacol*; 115: 981-986
- Khalil RA (2006). Dietary salt and hypertension: new molecular targets add more spice. *Am J Physiol Reg Integr Comp Physiol*; 290: R509-R513
- Kiernan JA (1999). *Histological and histochemical methods: theory and practice* (3rd Edn.); Butterworth Heinemann Publications, Oxford.
- Kim J, Ahn S, Ren XR, et al (2005). Functional antagonism of different G protein-coupled receptor kinases for β -arrestin-mediated angiotensin II receptor signaling. *PNAS USA*; 102: 1442-1447
- Kim S, Ohta K, Hamaguchi A, et al (1994). Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. *Kidney Int*; 46: 1346-1358
- King P, Peacock I, Donnelly R (1999). The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. *Br J Clin Pharmacol*; 48: 643-648
- Kippenberger S, Loitsch S, Guschel M, et al (2005). Mechanical stretch stimulates protein kinase b/Akt phosphorylation in epidermal cells via angiotensin II type I receptor and epidermal growth factor receptor. *J Biol Chem*; 280: 3060-3067
- Klusens LD, Nelemans SA, Rink R, et al (2009). Angiotensin-(1-7) with thioether bridge: an angiotensin converting enzyme resistant, potent angiotensin-(1-7) analog. *J Pharmacol Exp Ther*; 328: 849-855
- Knowlton KU, Michel MC, Itani M, et al (1993). The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. *J Biol Chem*; 268: 15374-15380

Bibliography

- Koenigsberger MR, Sauser M, Lamboley JL, et al (2004). Ca^{2+} dynamics in a population of smooth muscle cells: modeling the recruitment and synchronization. *Biophys J*; 87: 92-104
- Kopp UC (2011). Renorenal reflexes. In: *Neural control of renal function* (1st Edn; pp. 1-6); Morgan & Claypool Publishers, California.
- Kostis JB, Packer M, Black HR, et al (2004). Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. *Am J Hypertens*; 17: 103-111
- Kowala MC, Murugesan N, Tellew J, et al (2004). Novel dual action AT_1 and ET_A receptor antagonists reduce blood pressure in experimental hypertension. *J Pharmacol Exp Therap*; 309: 275-284
- Krebs LT, Kramar EA, Hanesworth JM, et al (1996). Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT_4 receptor antagonist. *Regulatory Peptides*; 67: 123-130
- Krum H, Schlaich M, Whitbourn R, et al (2009). Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. *Lancet*; 373: 1275-1281
- Krum H, Viskoper RJ, Lacourciere Y, et al (1998). The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension. *N Engl J Med*; 338: 784-791
- Ku DN (1997). Blood flow in arteries. *Ann Rev Fluid Mechanics*; 29: 399-434
- Kumar N, Calhoun DA, Dudenbostel T (2013). Management of patients with resistant hypertension: current treatment options. *Integr Blood Press Control*; 6: 139-151
- Kunes J, Kadlecova M, Vaneckova I, et al (2012). Critical developmental periods in the pathogenesis of hypertension. *Physiol Res*; 61: S9-S17
- Kuo YC, Huang KY, Yang CH, et al (2008). Regulation of Phosphorylation of Thr-308 of Akt, Cell Proliferation, and Survival by the $B55\alpha$ Regulatory Subunit Targeting of the Protein Phosphatase 2A Holoenzyme to Akt. *J Biol Chem*; 283: 1882-1892
- Kurtz TW, Griffin KA, Bidani AK, et al (2005). Recommendations for blood pressure measurement in humans and experimental animals Part 2: blood Pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the american heart association council on high blood pressure research. *Hypertension*; 45: 299-310

Bibliography

Kusuhara M, Takahashi E, Peterson TE, et al (1998). p38 Kinase is a negative regulator of angiotensin ii signal transduction in vascular smooth muscle cells: effects on Na^+/H^+ exchange and ERK1/2. *Circ Res*; 83: 824-831

Laneri S, Di Ronza C, Bernardi A, et al (2011). Synthesis and antihypertensive action of new imidazo [1,2-a] pyridine derivatives, non peptidic angiotensin ii receptor antagonists. *Cardiovasc Haematol Disorders-Drug Targets*; 11: 87-96

Lang CC, Rahman AR, Balfour DJ, et al (1992). Prazosin blunts the antinatriuretic effect of circulating angiotensin II in man. *J Hypertens*; 10: 1387-1395

Lassegue B, Alexander RW, Nickenig G, et al (1995). Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. *Mol Pharmacol*; 48: 601-609

Lea WB, Kwak ES, Luther JM, et al (2009). Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. *Kidney Int*; 75: 936-944

Lee DL, Webb RC, Jin L (2004). Hypertension and RhoA/Rho-kinase signaling in the vasculature : highlights from the recent literature. *Hypertension*; 44: 796-799

Legrand M, Payen D (2011). Understanding urine output in critically ill patients. *Annals Int Care*; 1: 13-21

Levy JH, Mancao MY, Gitter R, et al (2007). Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: The results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. *Anesth Analg*; 105: 918-925

Lezin ES, Griffin KA, Picken M, et al (1999). Genetic isolation of a chromosome 1 region affecting susceptibility to hypertension-induced renal damage in the spontaneously hypertensive rat. *Hypertension*; 34: 187-191

Li F, Malik KU (2005a). Angiotensin II-Induced Akt Activation through the Epidermal Growth Factor Receptor in Vascular Smooth Muscle Cells Is Mediated by Phospholipid Metabolites Derived by Activation of Phospholipase D. *J Pharmacol Exp Therap*; 312: 1043-1054

Li HT, Long CS, Gray MO, et al (1997). Cross Talk Between Angiotensin AT₁ and α_1 -Adrenergic Receptors: Angiotensin II Downregulates α_{1a} -Adrenergic Receptor Subtype mRNA and Density in Neonatal Rat Cardiac Myocytes. *Circ Res*; 81: 396-403

Li Z, Mao HZ, Abboud FM, et al (1996). Oxygen-Derived Free Radicals Contribute to Baroreceptor Dysfunction in Atherosclerotic Rabbits. *Circ Res*; 79: 802-811

Bibliography

Li F, Malik KU (2005b). Angiotensin II-induced Akt activation is mediated by metabolites of arachidonic acid generated by CaMKII-stimulated Ca²⁺-dependent phospholipase A2. *Am J Physiol Heart Circ Physiol*; 288: H2306-H2316

Lifton RP, Gharavi AG, Geller DS (2001). Molecular Mechanisms of Hypertension. *Cell*; 104: 545-556

Liles JT, Dabisch PA, Hude KE, et al (2006). Pressor responses to ephedrine are mediated by a direct mechanism in the rat. *J Pharmacol Exp Therap*; 316: 95-105

Lohmeier TE (2001). The sympathetic nervous system and long-term blood pressure regulation. *Am J Hypertens*; 14: 147S-154S

Loirand G, Guerin P, Pacaud P (2006). Rho kinases in cardiovascular physiology and pathophysiology. *Circ Res*; 98: 322-334

Long CS, Ordahl CP, Simpson PC (1989). Alpha 1-adrenergic receptor stimulation of sarcomeric actin isogene transcription in hypertrophy of cultured rat heart muscle cells. *J Clin Invest*; 83: 1078-1082

Louis WJ, Spector S, Tobei R, et al (1969). Synthesis and Turnover of Norepinephrine in the Heart of the Spontaneously Hypertensive Rat. *Circ Res*; 24: 85-91

Lula I, Denadai AL, Resende JM, et al (2007). Study of angiotensin-(1-7) peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. *Peptides*; 28: 2199-2210

Luttun A, Tjwa M, Moons L, et al (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nat Med*; 8: 831-840

Macrez N, Mironneau C, Carricaburu V, et al (2001). Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-Type Ca²⁺ channels. *Circ Res*; 89: 692-699

Maeso R, Navarro-Cid J, Munoz-Garcia R, et al (1996). Losartan Reduces Phenylephrine Constrictor Response in Aortic Rings From Spontaneously Hypertensive Rats: Role of Nitric Oxide and Angiotensin II Type 2 Receptors. *Hypertension*; 28: 967-972

Mancia G, Fagard R, Narkiewicz K, et al (2013). ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*; 34: 2159-2219

Bibliography

- Mancia G, Saino A, Grassi G (1995). Interactions between the sympathetic nervous system and the renin-angiotensin system. In: Hypertension: Pathophysiology, Diagnosis and Management (1st Edn; pp. 399); Raven Press, New York.
- Marcantoni C, Ma LJ, Federspiel C, et al (2002). Hypertensive nephrosclerosis in African Americans versus Caucasians. *Kidney Int*; 62: 172-180
- Mark AL (1996). The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. *J Hypertens*; 14: S159-S165
- Maron BA, Leopold JA (2010). Aldosterone receptor antagonists: effective but often forgotten. *Circulation*; 121: 934-939
- Marrero MB, Schieffer B, Li B, et al (1997). Role of janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. *J Biol Chem*; 272: 24684-24690
- Matoba T, Shimokawa H, Nakashima M, et al (2000). Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. *J Clin Invest*; 106: 1521-1530
- Matsui T, Tao J, del Monte F, et al (2001). Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. *Circulation*; 17: 330-335
- Maurer P, Bachmann MF (2010). Immunization against angiotensins for the treatment of hypertension. *Clin Immunol*; 134: 89-95
- Mazzali M, Kanbay M, Segal MS, et al (2010). Uric Acid and Hypertension: Cause or Effect? *Curr Rheumatol Rep*; 12: 108-117
- McPartland JM, Glass M, Pertwee RG (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. *Br J Pharmacol*; 152: 583-593
- Mehta P, Griendling KK (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. *Am J Physiol Cell Physiol*; 292: C82-C97
- Meier B (1996). Regulation of the superoxide releasing system in human fibroblasts. *Adv Exp Med Biol*; 387: 113-116
- Miller MR, Megson IL (2007). Recent developments in nitric oxide donor drugs. *Br J Pharmacol*; 151: 305-321
- Ming C, Yuhua L, Feng Z, et al (2006). Influence of antibody against AT1 receptor on blood pressure and kidney of spontaneous hypertensive rat. *J Immunol*; 22: 180-183

Bibliography

- Ming XF, Vishwambharan H, Barandier C, et al (2002). Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. *Mol Cell Biol*; 24: 8467-8477
- Mitchell JA, Nucci GDE, Warner TD, et al (1992). Different patterns of release of endothelium-derived relaxing factor and prostacyclin. *Br J Pharmacol*; 105: 485-489
- Miura Y, Yamamoto N, Tsunekawa S, et al (2005). Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. *Diabetes Care*; 28: 757-758
- Mohl M, Xiao XH, Balaji P, et al (2012). The α_{1A} -adrenergic receptor mediates cardiac hypertrophy through the G α_q -PI3K-Rac1 signaling pathway. *FASEB J*; 26: 663.4
- Molkentin JD, Don GW 2nd (2001). Cytoplasmic signaling pathways that regulate cardiac hypertrophy. *Annu Rev Physiol*; 63: 391-426
- Mombelli C, Giordani M, Imperiali N, et al (2013). Proteinuria/Creatininuria index and its correlation with the 24-hour proteinuria in renal transplanted patients. In: *Transplantation proceedings* (Vol. 45, No. 4, pp. 1635-1638); Elsevier, Philadelphia.
- Morello M, Perino A, Hirsch E (2009). Phosphoinositide-3-kinase signalling in the vascular system. *Cardiovasc Res*; 82: 261-271
- Moreno JJ (2009). New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. *Biochem Pharmacol*; 77: 1-10
- Morphy R, Kay C, Rankovic Z (2004). From magic bullets to designed multiple ligands. *Drug Discov Today*; 9: 641-651
- Morphy R, Rankovic Z (2005). Designed multiple ligands. an emerging drug discovery paradigm. *J Med Chem*; 48: 6523-6543
- Morphy R, Rankovic Z (2006). The physicochemical challenges of designing multiple ligands. *J Med Chem*; 49: 4961-4970
- Morphy R, Rankovic Z (2007). Fragments, network biology and designing multiple ligands. *Drug Discov Today*; 12: 156-160
- Morphy R, Rankovic Z (2009). Designing multiple ligands - medicinal chemistry strategies and challenges. *Curr Pharm Des*; 15: 587-600
- Morrison RG, Carpenter AB, Adams VL, et al (2005). Progression of renal damage in the obese Zucker rat in response to deoxycorticosterone acetate-salt-induced hypertension. *Ann Clin Lab Sci*; 35: 54-65

Bibliography

- Moser KA, Agrawal S, Smith GD, et al (2014). Socio-Demographic inequalities in the prevalence, diagnosis and management of hypertension in india: analysis of nationally-representative survey data. *PLoS One*; 9: e86043
- Mukoyama M, Nakajima M, Horiuchi M, et al (1993). Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. *J Biol Chem*; 268: 24539-24542
- Mulvany MJ (1993). Vascular remodelling in hypertension. *Eur Heart J*; 14: 2-4
- Murphy TJ, Alexander RW, Griendling KK, et al (1991). Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. *Nature*; 351: 233-236
- Murugesan N, Tellew JE, Gu Z, et al (2002). Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. *J Med Chem*; 45: 3829-3835
- Murugesan N, Gu Z, Fadnis L, et al (2005). Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2' -substituted n-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. *J Med Chem*; 48: 171-179
- Muth JN, Yamaguchi H, Mikala G, et al (1999). Cardiac-specific overexpression of the α_1 subunit of the L-type voltage-dependent Ca^{2+} channel in transgenic mice. *J Biol Chem*; 274: 21503-21506
- Naik P, Murumkar P, Giridhar R, et al (2010). Angiotensin II receptor type I (AT_1) selective nonpeptidic antagonists—A perspective. *Bioorg Med Chem*; 18: 8418-8456
- Namikoshi T, Satoh M, Horike H, et al (2006). Implication of peritubular capillary loss and altered expression of vascular endothelial growth factor in IgA nephropathy. *Nephron Physiol*; 102: 9-16
- Ndefo UA, Erowele GI, Ebiasah R, et al (2010). Clevidipine: A new intravenous option for the management of acute hypertension. *Am J Health Sys Pharmacy*; 67: 351-360
- Ndisang JF, Jadhav A (2010). Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension. *J Pharmacol Exp Therap*; 334: 87-98
- Neeli I, Yellaturu CR, Rao GN (2003). Arachidonic acid activation of translation initiation signaling in vascular smooth muscle cells. *Biochim Biophys Res Comm*; 309: 755-761
- Nguyen G, Delarue F, Burelle C, et al (2002). Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. *J Clin Invest*; 109: 1417-1427

Bibliography

- Nguyen G, Bueckle C, Sraer JD (2004). Renin/prorenin-receptor biochemistry and functional significance. *Curr Hypertens Rep*; 6: 129-132
- Nguyen G (2006). Renin/prorenin receptors. *Kidney Int*; 69: 1503-1506
- Nguyen G (2007). The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. *Curr Opin Nephrol Hypertens*; 16: 129-133
- Nguyen VA, Gao B (1999). Cross-talk between α_{1B} -adrenergic receptor ($\alpha_{1B}AR$) and interleukin-6 (IL-6) signaling pathways. *J Biol Chem*; 274: 35492-35498
- Nickenig G, Sachinidis A, Ko Y, et al (1996). Regulation of angiotensin AT₁ receptor gene expression during cell growth of vascular smooth muscle cells. *Eur J Pharmacol*; 297: 307-312
- Nickenig G, Sachinidis A, Michaelsen F, et al (1997a). Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. *Circulation*; 95: 473-478
- Nickenig G, Jung O, Strehlow K, et al (1997b). Hypercholesterolemia is associated with enhanced angiotensin AT₁-receptor expression. *Am J Physiol Heart Circ Physiol*; 272: H2701-H2707
- Nunes VW, Fortes ZB, Nigro D, et al (2000). Influence of enalapril on the endothelial function of DOCA-salt hypertensive rats. *General Pharmacology: The Vascular System*; 34: 117-125
- O'Donoghue TL, Brooks VL (2006). Deoxycorticosterone acetate-salt rats hypertension and sympathoexcitation driven by increased NaCl levels. *Hypertension*; 47: 680-685
- O'Shaughnessy KM, Karet FE (2006). Salt handling and hypertension. *Ann Rev Nutr*; 26: 343-365
- Ohmura T, Oshita M, Kigoshi S, et al (1992). Identification of α_1 -adrenoceptor subtypes in the rat vas deferens: binding and functional studies. *Br J Pharmacol*; 107: 697-704
- Oparil S, Zaman MA, Calhoun DA (2003). Pathogenesis of Hypertension. *Annals Intern Med*; 139: 761-776
- Oppermann M, Freedman MJ, Alexander RW, et al (1996). Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C. *J Biol Chem*; 271: 13266-13272
- Organization of Economic Cooperation & Development, OECD. OECD Guideline 407 for testing of chemicals, Repeat-dose oral toxicity. 2001

Bibliography

Organization of Economic Cooperation & Development, OECD. OECD Guideline 423 for testing of chemicals, acute oral toxicity. 2001

Ortmann J, Amann K, Brandes RP, et al (2004). Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. *Hypertension*; 44: 974-981

Oudit GY, Sun H, Kerfant BG (2004). The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. *J Mol Cell Cardiol*; 37: 449-471

Pacher P, Beckman JS, Liaudet L (2007). Nitric oxide and peroxynitrite in health and disease. *Physiol Rev*; 87: 315-424

Packer M, Califf RM, Konstam MA, et al (2002). Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). *Circulation*; 106: 920-926

Packer M, Colucci W, Fisher L, et al (2013). Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. *J Am Coll Cardiol Heart Failure*; 1: 103-111

Padia SH, Howell NL, Siragy HM, et al (2006). Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. *Hypertension*; 47: 537-544

Pagano PJ, Chanock SJ, Siwik DA, et al (1998). Angiotensin II induces p67phox mRNA expression and NADPH superoxide generation in rabbit aortic adventitial fibroblasts. *Hypertension*; 32: 331-337

Papay RS, Shi T, Piascik MT, et al (2013). α_{1A} -Adrenergic receptors regulate cardiac hypertrophy in vivo through interleukin-6 secretion. *Mol Pharmacol*; 83: 939-948

Parving IIII, Brenner BM, McMurray JJ (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*; 367: 2204-2213

Patel A, Sharif-Nacini R, Folgering JR, et al (2010). Canonical TRP channels and mechanotransduction: from physiology to disease states. *Pflugers Arch*; 460: 571-581

Paulis L, Unger T (2010). Novel therapeutic targets for hypertension. *Nat Rev Cardiol*; 7: 431-441

Payne RA, Wilkinson IB, Webb DJ (2010). Arterial stiffness and hypertension: emerging concepts. *Hypertension*; 55: 9-14

Peng H, Carretero OA, Alfie ME, et al (2001). Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene. *Hypertension*; 37: 974-980

Bibliography

- Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al (2003). A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA*; 290: 2805-2816
- Persson AE, Ollerstam A, Liu R, et al (2004). Mechanisms for macula densa cell release of renin. *Acta Physiol Scand*; 181: 471-474
- Peti-Peterdi J, Harris RC (2010). Macula densa sensing and signaling mechanisms of renin release. *J Am Soc Nephrol*; 21: 1093-1096
- Petrashevskaya NN, Bodi I, Koch SE, et al (2004). Effects of α_1 -adrenergic stimulation on normal and hypertrophied mouse hearts: relation to caveolin-3 expression. *Cardiovasc Res*; 63: 561-572
- Petrovsky N (2013). Unconventional vaccines: progress and challenges. *J Vaccines Vaccin*; 4: 4-8
- Piascik MT, Guarino RD, Smith MS, et al (1995). The specific contribution of the novel α_1 -D adrenoceptor to the contraction of vascular smooth muscle. *J Pharmacol Exp Therap*; 275: 1583-1589
- Piascik MT, Hrometz SL, Edelman SE, et al (1997). Immunocytochemical localization of the α_1 -b adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: analysis with selective ligands and antisense oligonucleotides. *J Pharmacol Exp Therap*; 283: 854-868
- Piascik MT, Perez DM (2001). α_1 -Adrenergic receptors: new insights and directions. *J Pharmacol Exp Therap*; 298: 403-410
- Pohl MA (1997). Renal artery stenosis, renal vascular hypertension and ischemic nephropathy. In: *Diseases of the Kidney* (6th Edn; pp. 1367); Little Brown and Company, New York
- Pous-Torres S, Torres-Lapasió J, Ruiz-Ángel MJ, et al (2009). Interpretive optimisation of organic solvent content and flow-rate in the separation of β -blockers with a Chromolith RP-18e column. *J Sep Sci*; 32: 2793-2803
- Puddu P, Puddu GM, Zacca F, et al (2000). Endothelial dysfunction in hypertension. *Acta Cardiologica*; 55: 221-232
- Quigley R, Chakravarty S, Zhao X, et al (2009). Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. *Nephron Physiol*; 113: 23-28

Bibliography

- Quignard JF, Mironneau J, Carricaburu V, et al (2001). Phosphoinositide 3-kinase mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. *J Biol Chem*; 276: 32545-32551
- Rahn KH (1992). Clinical experience with dual-acting drugs in hypertension. *Clin Investig*; 70: S39-S42
- Rao RN, Nagaraju D, Jena N, et al (2006). Development and validation of a reversed-phase HPLC method for monitoring of synthetic reactions during the manufacture of a key intermediate of an anti-hypertensive drug. *J Sep Sci*; 29: 2303-2309
- Reid IA (1992). Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. *Am J Physiol*; 262: E763-E778
- Reit E (1972). Actions of angiotensin on the adrenal medulla and autonomic ganglia. *Fed Proc*; 31: 1338-1343
- Rhaleb NE, Pokharel S, Sharma U, et al (2011). Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in DOCA-salt hypertensive mice. *J Hypertens*; 29: 330-338
- Rich MW (2000). Uric acid: is it a risk factor for cardiovascular disease? *Am J Cardiol*; 85: 1018-1021
- Rieckert, H. (1996). Orthostatic hypotension: how to avoid it during antihypertensive therapy. *Am J Hypertens*; 9: 155S-159S
- Rizzoni D, Porteri E, Duse S, et al (2012). Relationship between media-to-lumen ratio of subcutaneous small arteries and wall-to-lumen ratio of retinal arterioles evaluated noninvasively by scanning laser Doppler flowmetry. *J Hypertens*; 30: 1169-1175
- Roberts JA, Pea F, Lipman J (2013). The clinical relevance of plasma protein binding changes. *Clin Pharmacokinet*; 52: 1-8
- Robinson MJ, Cobb MH (1997). Mitogen-activated protein kinase pathways. *Curr Opin Cell Biol*; 9: 180-186
- Rokosh DG, Simpson PC (2002). Knockout of the $\alpha_{1A/C}$ -adrenergic receptor subtype: The $\alpha_{1A/C}$ is expressed in resistance arteries and is required to maintain arterial blood pressure. *PNAS USA*; 99: 9474-9479
- Rosei EA, Rizzoni D, Castellano M, et al (1995). Media: lumen ratio in human small resistance arteries is related to forearm minimal vascular resistance. *J Hypertens*; 13: 279-373
- Rosivall L (2009). Intrarenal renin-angiotensin system. *Mol Cell Endocrinol*; 302: 185-192

Bibliography

- Rossi F, Bertone C, Petricca S, et al (2006). Adrenomedullin antagonizes angiotensin II-stimulated proliferation of human aortic smooth muscle cells. *Peptides*; 27: 2935-2941
- Rossi F, Bertone C, Petricca S, et al (2007). Ghrelin inhibits angiotensin II-induced migration of human aortic endothelial cells. *Atherosclerosis*; 192: 291-297
- Rossier O, Abuin L, Fanelli F, et al (1999). Inverse agonism and neutral antagonism at α_{1a} - and α_{1b} -adrenergic receptor subtypes. *Mol Pharmacol*; 56: 858-866
- Rowell LB (1993). *Human cardiovascular control* (10th Edn., pp. 1-520); Oxford University Press, USA.
- Ryckmans T, Balancon L, Berton O, et al (2002). First dual NK₁ antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants. *Bioorg Med Chem Lett*; 12: 261-264
- Sacks FM, Svetkey LP, Vollmer WM, et al (2001). Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med*; 344: 3-10
- Sahan-Firat S, Jennings BL, Yaghini FA, et al (2010). 2, 3', 4, 5'-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. *Am J Physiol Heart Circ Physiol*; 299: H1891-H1901
- Sakata Y, Nakatani D, Shimizu M, et al (2012). Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. *J Cardiol*; 59: 14-21
- Salvi P (2012). Mean Arterial Pressure. In: *Pulse Waves: how vascular dynamics affect blood pressure?* (1st Edn; pp. 3-7); Springer Publications, London.
- Sasaki K, Yamano Y, Bardhan S, et al (1991). Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. *Nature*; 351: 230-233
- Sata M, Nagai R (2002). Phosphatidylinositol-3-kinase: a key regulator of vascular tone? *Circ Res*; 91: 273-275
- Savergnini SQ, Beiman M, Lautner RQ, et al (2010). Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. *Hypertension*; 56: 112-120
- Savergnini SQ, Ianzer D, Carvalho MBL, et al (2013). The Novel Mas agonist, CGEN-856S, Attenuates Isoproterenol-Induced Cardiac Remodeling and Myocardial Infarction Injury in Rats. *PLoS One*; 8: e57757

Bibliography

- Saward L, Zahradka P (1997). Angiotensin II activates phosphatidylinositol-3-kinase in vascular smooth muscle cells. *Circ Res*; 81: 249-257
- Scheffé JH, Menk M, Reinemund J, et al (2006). A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. *Circ Res*; 99: 1355-1366
- Scheffé JH, Neumann C, Goebel M, et al (2008). Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. *J Hypertens*; 26: 1787-1794
- Schenk J, McNeill JH (1992). The pathogenesis of DOCA-salt hypertension. *J Pharmacol Toxicol Methods*; 27: 161-170
- Schlaich M, Sobotka PA, Krum H, et al (2009). Renal sympathetic-nerve ablation for uncontrolled hypertension. *N Engl J Med*; 361: 9324-934
- Schulz E, Jansen T, Wenzel P, et al (2008). Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. *Antioxidants Redox Signal*; 10: 1115-1126
- Schumacher CD, Steele RE, Brunner HR (2013). Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. *J Hypertens*; 31: 2085-2093
- Schwinn DA, Page SO, Middleton JP, et al (1991). The α_{1C} -adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. *Mol Pharmacol*; 40: 619-626
- Schwinn DA, Johnston GI, Page SO, et al (1995). Cloning and pharmacological characterization of human α_1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. *J Pharmacol Exp Therap*; 272: 134-142
- Schyler S, Horuk R (2006). I want a new drug: G-protein-coupled receptors in drug development. *Drug Discov Today*; 11: 481-493
- Scultz HD, Li YL, Ding Y (2007). Arterial chemoreceptors and sympathetic nerve activity. *Hypertension*; 50: 6-13
- Seidelin PH, Coutie WJ, Pai MS, et al (1987). The interaction between noradrenaline and angiotensin II in man: evidence for a postsynaptic and against a presynaptic interaction. *J Hypertens*; 5: S121-S124
- Seifi B, Kadkhodae M, Karimian SM, et al (2010). Evaluation of renal oxidative stress in the development of DOCA-salt induced hypertension and its renal damage. *Clin Exp Hypertens*; 32: 90-97

Bibliography

- Seki T, Yokoshiki H, Sunagawa L, et al (1999). Angiotensin II stimulation of Ca²⁺-channel current in vascular smooth muscle cells is inhibited by lavendustin-A and LY-294002. *Pflugers Arch*; 437: 317-323
- Sessa WC (2010). A new way to lower blood pressure: pass the chilli peppers please! *Cell Metab*; 12: 109-110
- Shah NS, Billimoria AR, Mukherjee S, et al (2013). Management of Hypertension. *J Assoc Physicians India*; 61: 17-23
- Shemesh R, ToporiK A, Levine Z, et al (2008). Discovery and validation of novel peptide agonists for G-protein-coupled receptors. *J Biol Chem*; 283: 34643-34649
- Shepherd JT, Mancia G (1986). Reflex control of the human cardiovascular system. *Rev Physiol Biochem Pharmacol*; 105: 1-99
- Shigematsu K, Koyama H, Olson NE, et al (2000). Phosphatidylinositol 3-kinase signaling is important for smooth muscle cell replication after arterial injury. *Arterioscler Thromb Vasc Biol*; 20: 2373-2378
- Shiojima I, Walsh K (2002). Role of Akt Signaling in Vascular Homeostasis and Angiogenesis. *Circ Res*; 90: 1243-1250
- Shrivastava A, Gupta VB (2012). Stability-Indicating RP-HPLC method for the simultaneous determination of prazosin, terazosin, and doxazosin in pharmaceutical formulations. *Scientia Pharmaceutica*; 80: 619-631
- Silva-Barcellos NM, Caligiorme S, Santos RAS, et al (2004). Site-specific microinjection of liposomes into the brain for local infusion of a short-lived peptide. *J Controlled Release*; 95: 301-307
- Singla N, Wartier D, Gandhi S, et al (2008). Treatment of acute postoperative hypertension in cardiac surgery patients: An efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. *Anesth Analg*; 107: 59-67
- Sinha NK, Asnani AJ, Dravyaka BR (2013). A novel approach towards development of quinazoline derivatives in pain management. *Asian J Pharm Clin Res*; 6: 200-204
- Sleight P (2000). The HOPE Study (Heart Outcomes Prevention Evaluation). *J Renin Angiotensin Aldosterone Syst*; 1: 18-20
- Smith HW (1959). *From fish to philosopher: the story of our internal environment* (1st Edn., pp. 1-304); Ciba Publications, New York.
- Smith SA, Williams MA, Leal AK, et al (2006). Exercise pressor reflex function is altered in spontaneously hypertensive rats. *J Physiol*; 577: 1009-1020

Bibliography

Solomon SD, Zile M, Pieske B, et al (2012). The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet*; 380: 1387-1395

Somers VK, Dyken ME, Clary MP, et al (1995). Sympathetic neural mechanisms in obstructive sleep apnea. *J Clin Invest*; 96: 1897-1904

Sripalakit P, Nermhom P, Saraphanchotiwitthaya A (2005). Improvement of doxazosin determination in human plasma using high-performance liquid chromatography with fluorescence detection. *J Chrom Sci*; 43: 63-66

Stanasila L, Perez JB, Vogel H, et al (2003). Oligomerization of the α_{1A} - and α_{1B} -adrenergic receptor subtypes. *J Biol Chem*; 278: 40239-40251

Stanasila L, Abuin L, Dey J, et al (2008). Different internalization properties of the α_{1A} - and α_{1B} -adrenergic receptor subtypes: the potential role of receptor interaction with β -arrestins and AP50. *Mol Pharmacol*; 74: 562-573

Starke K (1977). Regulation of noradrenaline release by presynaptic receptor systems. *Rev Physiol Biochem Pharmacol*; 77: 1-124

Stassen FR, Willemsen MJ, Janssen GM, et al (1997). α_1 -Adrenoceptor subtypes in rat aorta and mesenteric small arteries are preserved during left ventricular dysfunction post-myocardial infarction. *Cardiovasc Res*; 33: 706-713

Sultana N, Arayne MS, Shah SN (2013). Liquid chromatographic analysis of prazosin in API, dosage form and serum: application to drug-metal interaction studies. *J Chrom Sep Techniq*; 4: 197

Sun H, Li DP, Chen SR, et al (2009). Sensing of blood pressure increase by transient receptor potential vanilloid 1 receptors on baroreceptors. *J Pharmacol Exp Ther*; 331: 851-859

Susic D, Zhou X, Frohlich ED, et al (2008). Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. *Am J Physiol Heart Circ Physiol*; 295: H1171-H1121

Szasz T, Watts SW (2010). Uric acid does not affect the acetylcholine-induced relaxation of aorta from normotensive and deoxycorticosterone acetate-salt hypertensive rats. *J Pharmacol Exp Therap*; 333: 758-763

Taguchi K, Yang M, Goepel M, et al (1998). Comparison of human α_1 -adrenoceptor subtype coupling to protein kinase C activation and related signalling pathways. *Naunyn-Schmeideberg's Arch Pharmacol*; 357: 100-110

Bibliography

- Takagi M, Atarashi K, Matsuoka H, et al (1992). A biphasic effect of noradrenaline on renin release from rat juxtaglomerular cells in vitro is mediated by α 1- and β -adrenoceptors. *J Endocrinol*; 132: 133-140
- Takahashi T, Taniguchi T, Konishi H, et al (1999a). Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol*; 276: H1927-H1934
- Takahashi T, Ueno H, Shibuya M (1999b). VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. *Oncogene*; 18: 2221-2230
- Take H, Shibata K, Awaji T, et al (1998). Vascular α 1-adrenoceptor subtype selectivity and α 1-blocker-induced orthostatic hypotension. *Jpn J Pharmacol*; 77: 61-70
- Takeda K, Ichiki T, Tokunou T, et al (2000). Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type I receptor in vascular smooth muscle cells. *Circulation*; 102: 1834-1839
- Tanoue A, Koba M, Miyawaki S, et al (2002). Role of the α_{1D} -adrenergic receptor in the development of salt-induced hypertension. *Hypertension*; 40: 101-106
- Tepel M, Jankowski J, Ruess C, et al (1998). Activation of Na^+ - H^+ exchanger produces vasoconstriction of renal resistance vessels. *Am J Hypertens*; 11: 1214-1221
- Theroux TL, Esbenshade TA, Peavy RD, et al (1996). Coupling efficiencies of human α 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors. *Mol Pharmacol*; 50: 1376-1387
- Tipnis SR, Hooper NM, Hyde R, et al (2000). A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. *J Biol Chem*; 275: 33238-33243
- Tissot AC, Maurer P, Nussberger J, et al (2008). Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. *Lancet*; 371: 821-827
- Toker A, Newton AC (2000). Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. *J Biol Chem*; 275: 8271-8274
- Tom B, Dendorfer A, Danser AHJ (2003). Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? *Int J Biochem Cell Biol*; 35: 792-801
- Tomaschitz A, Maerz W, Pilz S, et al (2010). Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. *J Am Coll Cardiol*; 55: 2171-2180

Bibliography

Tomlinson B, Cronin CJ, Graham BR, et al (1987). Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. *J Cardiovasc Pharmacol*; 10: 101-109

Touyz RM, Schiffrin EL (1997). Angiotensin II regulates vascular smooth muscle cell pH, contraction, and growth via tyrosine kinase-dependent signaling pathways. *Hypertension*; 30: 222-229

Touyz RM, El Mabrouk M, He G, et al (1999). Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. *Circ res*; 84: 505-515

Touyz RM, Schiffrin EL (2000). Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. *Pharmacol Rev*; 52: 639-672

Turner AJ, Isaac RE, Coates D (2001). The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. *Bioessays*; 23: 261-269

Uckun FM, Ek O, Liu XP, et al (1999). In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4' hydroxyphenyl)-amino-6, 7-dimethoxyquinazoline]. *Clin Cancer Res*; 5: 2954-2962

Ulu N, Gurdal H, Landheer SW, et al (2010). α_1 -Adrenoceptor-mediated contraction of rat aorta is partly mediated via transactivation of the epidermal growth factor receptor. *Br J Pharmacol*; 161: 1301-1310

Umans JG, Levi R (1995). Nitric oxide in the regulation of blood flow and arterial pressure. *Ann Rev Physiol*; 57: 771-790

Ushio-Fukai M, Alexander RW, Akers M, et al (1999). Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. *J Biol Chem*; 274: 22699-22704

van Zwieten PA and de Jonge A (1986). Interaction between the adrenergic and renin-angiotensin-aldosterone-systems. *Postgrad Med J*; 62: 23-27

Vanhaesebroeck B, Guillemer-Guilbert J, Graupera M, et al (2010). The emerging mechanisms of isoform-specific PI3K signaling. *Nat Rev Mol Cell Biol*; 11: 329-341

Viard P, Butcher AJ, Halet G, et al (2004). PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. *Nat Neurosci*; 7: 939-946

Villalobos-Molina R, Lopez-Guerrero JJ, Ibarra M (1999). Functional evidence of α_{1D} -adrenoceptors in the vasculature of young and adult spontaneously hypertensive rats. *Br J Pharmacol*; 126: 1534-1536

Bibliography

Villalobos-Molina R, Vazquez-Cuevas FG, Lopez-Guerrero JJ, et al (2008). Vascular α_{1D} -adrenoceptors are overexpressed in aorta of the aryl hydrocarbon receptor null mouse: role of increased angiotensin II. *Autonomic Autacoid Pharmacol*; 28: 61-67

Vincent JL (2008). Understanding Cardiac Output. *Critical Care*; 12: 174-176

Vittorio T, Fudim M, Wagman G, et al (2014). Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine. *Cardiol Rev*; 22: 51-55

Wakatsuki T, Schlessinger J, Elson EL (2004). The biochemical response of the heart to hypertension and exercise. *Trends Biochem Sci*; 29: 609-617

Walsh TF, Fitch KJ, Williams DL Jr, et al (1995). Potent dual antagonists of endothelin and angiotensin II receptors derived from α -phenoxyphenylacetic acids (Part III). *Bioorg Med Chem Lett*; 5: 1155-1158

Wang L, Feng YH, Gorodeski GI (2005). Epidermal growth factor facilitates epinephrine inhibition of P2X7-receptor-mediated pore formation and apoptosis: a novel signaling network. *Endocrinology*; 146: 164-174

Wang Y, Wang DH (2009). Aggravated renal inflammatory responses in TRPV1 gene knockout mice subjected to DOCA-salt hypertension. *Am J Physiol Renal Physiol*; 297: F1550-F1559

Webb RC, Bohr DF (1981). What makes the pressure go up? A hypothesis. *Hypertension* 1981; 3: 160-165

Weber MA, Schiffrin EL, White WB, et al (2014). Clinical practice guidelines for the management of hypertension in the community. *J Clin Hypertens*; 16: 14-26

Weder AB (2007). Evolution and hypertension. *Hypertension*; 49: 260-265

Wee S, Mandyam CD, Lekic DM, et al (2008). α_1 -Noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. *European Neuropsychopharmacol*; 18: 303-311

Wei D, Jiang X, Zhou L, et al (2008). Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. *J Med Chem*; 51: 7882-7888

Wermuth CG (2004). Multitargeted drugs: the end of the "one-target-one-disease" philosophy? *Drug Discov Today*; 9: 826-827

Wess J (1997). G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. *FASEB J*; 11: 346-354

Bibliography

Williams B, Poulter NR, Brown MJ, et al (2004). Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. *J Human Hypertens*; 18: 139-185

Wolff DW, Buckalew VM Jr, Strandhoy JW (1984). Renal α_1 - and α_2 -adrenoceptor mediated vasoconstriction in dogs: Comparison of phenylephrine, clonidine, and guanabenz. *J Cardiovasc Pharmacol*; 6: S793-S798

Wright JW, Harding JW (1997). Important roles for angiotensin III and IV in the brain renin-angiotensin system. *Brain Res Rev*; 25: 96-124

Wu M, Huang Z, Xie H, et al (2013). Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. *PLoS One*; 8: e78231

Wymann MP, Pirola L (1998). Structure and function of phosphoinositide 3-kinases. *Biochim Biophys Acta Mol Cell Biol Lipid*; 1436: 127-150

Xiao RP, Zhu W, Zheng M, et al (2006). Subtype-specific α_1 - and β -adrenoceptor signaling in the heart. *Trends Pharmacol Sci*; 27: 330-337

Xie PL, McDowell TS, Chapleau MW, et al (1990). Mechanism of decreased baroreceptor activity in chronic hypertensive rabbits. Role of endogenous prostanoids. *J Clin Invest*; 86: 625-630

Xie PL, McDowell TS, Chapleau MW, et al (1991). Rapid baroreceptor resetting in chronic hypertension. Implications for normalization of arterial pressure. *Hypertension*; 17: 72-79

Xu J, Li G, Wang P, et al (2005). Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. *J Clin Invest*; 115: 1275-1280

Yamada S, Yamamura HI, Roeske WR (1980). Characterization of alpha-1 adrenergic receptors in the heart using [3H]WB4101: effect of 6-hydroxydopamine treatment. *J Pharmacol Exp Therap*; 215: 176-185

Yamamoto Y, Koike K (2001). Characterization of α_1 -receptor mediated contraction in the mouse thoracic aorta. *Eur J Pharmacol*; 424: 131-140

Yamboliev IA, Mutafova-Yambolieva VN (2005). PI3K and PKC contribute to membrane depolarization mediated by α_2 -adrenoceptors in the canine isolated mesenteric vein. *BMC Physiol*; 5: 9

Yang D, Luo Z, Ma S, et al (2010). Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. *Cell Metab*; 12: 130-141

Bibliography

Yang H, Raizada MK (1999). Role of phosphatidylinositol 3-kinase in angiotensin II regulation of norepinephrine neuromodulation in brain neurons of the spontaneously hypertensive rat. *J Neurosci*; 19: 2413-2423

Yano Y, Hoshida S, Ishikawa J, et al (2007). The differential effects of angiotensin II type I receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. *Am J Hypertens*; 20: 565-572

- Yeldandi AV, Yeldandi V, Kumar S, et al (1991). Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. *Gene*; 109: 281-284

Yemane H, Busauskas M, Burris SK, et al (2010). Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats. *Exp Physiol*; 95: 51-55

Yu SM, Tsai SY, Guh JH, et al (1996). Mechanism of catecholamine-induced proliferation of vascular smooth muscle cells. *Circulation*; 94: 547-554

Zayed MF, Hassan MH (2013). Design, synthesis and biological evaluation studies of novel quinazoline derivatives as cytotoxic agents. *Drug Res*; 63: 210-215

Zhong H, Minneman KP (1999). α_1 -Adrenoceptor subtypes. *Eur J Pharmacol*; 375: 261-276

Zhou MS, Nishida Y, Yoneyama H, et al (1999). Potassium supplementation increases sodium excretion and nitric oxide production in hypertensive Dahl rats. *Clin Exp Hypertens*; 21: 1397-1411

Zhu F, Liao Y, Li L, et al (2006). Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. *Cell Mol Immunol*; 3: 107-114

Ziegler MG, Mills P, Dimsdale JE (1991). Hypertensives' Pressor Response to Norepinephrine. *Am J Hypertens*; 4: 586-591

Zimmerman BG, Sybertz EJ, Wong PC. (1984). Interaction between sympathetic and renin-angiotensin system. *J Hypertens*; 2: 581-587

Zimmerman GR, Lehar J, Keith CT (2007). Multi-target therapeutics: when the whole is greater than the sum of the parts. *Drug Discov Today*; 12: 34-42

Zuscik MJ, Chalothorn D, Hellard D, et al (2001). Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the α_{1b} -adrenergic receptor. *J Biol Chem*; 276: 13738-13743

BIBLIOGRAPHY

COPYRIGHT © HARDIK GANDHI

BIBLIOGRAPHY

BIBLIOGRAPHY

Akopian D, Medh JD (2006). Genetics and molecular biology: Macrophage ACAT depletion - mechanisms of atherogenesis. *Curr Opin Lipidol*; 17: 85-88

An S, Cho KH, Lee WS, et al (2006). A critical role for the histidine residues in the catalytic function of acyl-coa:Cholesterol acyltransferase catalysis: Evidence for catalytic difference between ACAT1 and ACAT2. *FEBS Lett*; 580: 2741-2749

Anderson RA, Joyce C, Davis M, et al (1998). Identification of a form of acyl-coa:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. *J Biol Chem*; 273: 26747-26754

Aragane K, Kusunoki J, Kitamine T, et al (1998). Effects of F-1394, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: possible role of hepatic ACAT in very low density lipoprotein secretion. *Jpn J Pharmacol*; 76: 309-312

Asano S, Ban H, Kino K, et al (2009). Novel 1, 4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: dual effectors on acyl-CoA: cholesterol-O-acyltransferase and low-density lipoprotein receptor expression. *Bioorg Med Chem Lett*; 19: 1062-1065

Bell TA, Brown JM, Graham MJ, et al (2006). Liver-specific inhibition of acyl-coenzyme a:Cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice. *Arterioscler Thromb Vasc Biol*; 26: 1814-1820

Bertram L, McQueen MB, Mullin K, et al (2007). Systematic meta-analyses of alzheimer disease genetic association studies: The alzgene database. *Nat Genet*; 39: 17-23

Boylan JG, Hamilton JA (1992). Interactions of acyl-coenzyme a with phosphatidylcholine bilayers and serum albumin. *Biochemistry*; 31: 557-567

Brown MS, Goldstein JL (1983). Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. *Annu Rev Biochem*; 52: 223-261

Brown MS, Goldstein JL, Krieger M, et al (1979). Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. *J Cell Biol*; 82: 597-613

Buhman KF, Accad M & Farese RV (2000a). Mammalian acyl-coa:cholesterol acyltransferases. *Biochim Biophys Acta*; 1529: 142-154

BIBLIOGRAPHY

Buhman KK, Accad M, Novak S, et al (2000b). Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. *Nat Med*; 6: 1341-1347

Buhman KK, Chen HC & Farese RV, Jr. (2001). The enzymes of neutral lipid synthesis. *J Biol Chem*; 276: 40369-40372

Burnett JR (2003). Eflucimibe. Pierre Fabre/Eli Lilly. *Curr Opin Investig Drugs*; 4: 347-351

Burnett JR, Wilcox LJ, Huff MW (1999a). Acyl coenzyme a: Cholesterol acyltransferase inhibition and hepatic apolipoprotein b secretion. *Clin Chim Acta*; 286: 231-242

Burnett JR, Wilcox LJ, Telford DE, et al (1999). Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. *J Lip Res*; 40: 1317-1327

Cao G, Goldstein JL, Brown MS (1996). Complementation of mutation in acyl-coa:cholesterol acyltransferase (ACAT) fails to restore sterol regulation in ACAT-defective sterol-resistant hamster cells. *J Biol Chem*; 271: 14642-14648

Cao XZ, Mi TY, Li L, et al (2013). HPLC-FLD determination of NBD-cholesterol, its ester and other metabolites in cellular lipid extracts. *Biomed Chromatogr*; 27: 910-915

Cases S, Novak S, Zheng YW, et al (1998). ACAT-2, a second mammalian acyl-CoA: cholesterol acyltransferase its cloning, expression, and characterization. *J Biol Chem*; 273: 26755-26764

Chakravarty B, Gu Z, Chirala SS, et al (2004). Human fatty acid synthase: Structure and substrate selectivity of the thioesterase domain. *PNAS USA*; 101: 15567-15572

Chang CC, Huh HY, Cadigan KM, et al (1993). Molecular cloning and functional expression of human acyl-coenzyme A: cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. *J Biol Chem*; 268: 20747-20755

Chang CC, Noll W, Nutile-McMenemy N, et al (1994). Localization of acyl coenzyme a:Cholesterol acyltransferase gene to human chromosome 1q25. *Somat Cell Mol Genet*; 20: 71-74

Chang CC, Chen J, Thomas MA, et al (1995). Regulation and immunolocalization of acyl-coenzyme a: Cholesterol acyltransferase in mammalian cells as studied with specific antibodies. *J Biol Chem*; 270: 29532-29540

Chang CC, Lee CY, Chang ET, et al (1998). Recombinant acyl-CoA: cholesterol acyltransferase-I (ACAT-1) purified to essential homogeneity utilizes cholesterol in

BIBLIOGRAPHY

- mixed micelles or in vesicles in a highly cooperative manner. *J Biol Chem*; 273: 35132-35141
- Chang CC, Sakashita N, Ornvold K, et al (2000). Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. *J Biol Chem*; 275: 28083-28092
- Chang CC, Dong R, Miyazaki A, et al (2006). Human acyl-coa:Cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis. *Acta Biochim Biophys Sin (Shanghai)*; 38: 151-6
- Chang CC, Sun J, Chang TY (2011). Membrane-bound o-acyltransferases (MBOATs). *Front Biol*; 6: 177-182
- Chang TY, Chang CC, Cheng D (1997). Acyl-coenzyme a:cholesterol acyltransferase. *Annu Rev Biochem*; 66: 613-638
- Chang TY, Chang CC, Lu X, et al (2001). Catalysis of ACAT may be completed within the plane of the membrane: A working hypothesis. *J Lipid Res*; 42: 1933-1938
- Chang TY, Chang CC, Ohgami N, et al (2006b). Cholesterol sensing, trafficking, and esterification. *Annu Rev Cell Dev Biol*; 22: 129-157
- Chang TY, Li BL, Chang CC, et al (2009). Acyl-coenzyme a:cholesterol acyltransferases. *Am J Physiol Endocrinol Metab*; 297: E1-E9
- Chang TY, Chang CC, Bryleva E, et al (2010). Neuronal cholesterol esterification by ACAT1 in alzheimer's disease. *IUBMB Life*; 62: 261-267
- Cheng D, Chang CC, Qu X, et al (1995a). Activation of acyl-coenzyme a:Cholesterol acyltransferase by cholesterol or by oxysterol in a cell-free system. *J Biol Chem*; 270: 685-95
- Cheng W, Kvilekval KV, Abumrad NA (1995b). Dexamethasone enhances accumulation of cholesteryl esters by human macrophages. *Am J Physiol*; 269: E642-E648
- Chiwata T, Aragane K, Fujinami K, et al (2001). Direct effect of an acyl-CoA: cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. *Br J Pharmacol*; 133: 1005-1012
- Cho KH, An S, Lee WS, et al (2003). Mass-production of human ACAT-1 and ACAT-2 to screen isoform-specific inhibitor: a different substrate specificity and inhibitory regulation. *Biochem Biophys Res Commun*; 309: 864-872

BIBLIOGRAPHY

- Civen M, Leeb J & Morin RJ (1982). Relationships between circadian cycles of rat adrenal cholesterol ester metabolizing enzymes, cholesterol, ascorbic acid, and corticosteroid secretion. *J Steroid Biochem*; 16: 817-822
- Colell A, Fernandez A, Fernandez-Checa JC (2009). Mitochondria, cholesterol and amyloid beta peptide: A dangerous trio in alzheimer disease. *J Bioenerg Biomembr*; 41: 417-423
- Coleman RA, Boyer PD, Bell RM (1983). Topography of membrane-bound enzymes that metabolize complex lipids. In: *The enzymes* (3rd Edn., pp. 605-625); Academic Press, New York.
- Das A, Davis MA, Rudel LL (2008). Identification of putative active site residues of ACAT enzymes. *J Lipid Res*; 49: 1770-1781
- de Medina P, Payré BL, Bernad J, et al (2004). Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. *J Pharmacol Exp Therap*; 308: 1165-1173
- Dominick MA, Bobrowski WA, Macdonald JR, et al (1993a). Morphogenesis of a zone-specific adrenocortical cytotoxicity in guinea pigs administered PD 132301-2, an inhibitor of acyl-CoA: cholesterol acyltransferase. *Toxicol Pathol*; 21: 54-62
- Dominick MA, McGuire EJ, Reindel JF, et al (1993b). Subacute toxicity of a novel inhibitor of acyl-CoA: cholesterol acyltransferase in beagle dogs. *Toxicol Sci*; 20: 217-224
- Doolittle GM, Chang TY (1982). Solubilization, partial purification, and reconstitution in phosphatidylcholine-cholesterol liposomes of acyl-coa:Cholesterol acyltransferase. *Biochemistry*; 21: 674-679
- Echavarri C, Caballero MC, Aramendia A, et al (2011). Multiprotein deposits in neurodegenerative disorders: our experience in the tissue brain bank of navarra. *Anat Rec (Hoboken)*; 294: 1191-1197
- Erickson SK, Cooper AD (1980a). Acyl-coenzyme A: Cholesterol acyltransferase in human liver. In vitro detection and some characteristics of the enzyme. *Metabolism*; 29: 991-996
- Erickson SK, Shrewsbury MA, Brooks C, et al (1980b). Rat liver acyl-coenzyme a:Cholesterol acyltransferase: Its regulation in vivo and some of its properties in vitro. *J Lipid Res*; 21: 930-941
- Falk E, Shah PK, Fuster V (1995). Coronary plaque disruption. *Circulation*; 92: 657-671
- Falk E (2006). Pathogenesis of atherosclerosis. *J Am Coll Cardiol*; 47: C7-C12

BIBLIOGRAPHY

- Farese RV (2006). The nine lives of ACAT inhibitors. *Arterioscler Thromb Vasc Biol*; 26: 1684-1686
- Fazio S, Major AS, Swift LL, et al (2001). Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. *J Clin Invest*; 107: 163-171
- Furukawa K, Hori M, Ouchi N, et al (2004). Adiponectin down-regulates acyl-coenzyme a:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. *Biochem Biophys Res Commun*; 317: 831-836
- Gandhi H, Upaganlawar A & Balaraman R (2010). Adipocytokines: The pied pipers. *J Pharmacol Pharmacother*; 1: 9-17
- Gelain A, Bettinelli I, Barlocco D, et al (2006). Ureidopyridazine derivatives as acyl-CoA: cholesterol acyltransferase inhibitors. *Scienza pharmaceutica*; 74: 85-97
- Ghosh S, Zhao B, Bie J, et al (2010). Macrophage cholesteryl ester mobilization and atherosclerosis. *Vasc Pharmacol*; 52: 1-10
- Glomset JA (1968). The plasma lecithins:cholesterol acyltransferase reaction. *J Lipid Res*; 9: 155-167
- Glomset JA (1973). The metabolic role of lecithin: cholesterol acyltransferase: Perspectives from pathology. *Adv Lipid Res*; 11: 1-65
- Goodman DS, Deykin D, Shiratori T (1964). The formation of cholesterol esters with rat liver enzymes. *J Biol Chem*; 239: 1335-1345
- Guo Z, Cromley D, Billheimer JT, et al (2001). Identification of potential substrate-binding sites in yeast and human acyl-coa sterol acyltransferases by mutagenesis of conserved sequences. *J Lipid Res*; 42: 1282-1291
- Guo ZY, Chang CC, Lu X, et al (2005a). The disulfide linkage and the free sulfhydryl accessibility of acyl-coenzyme a:cholesterol acyltransferase 1 as studied by using mpeg5000-maleimide. *Biochemistry*; 44: 6537-6546
- Guo ZY, Lin S, Heinen JA, et al (2005b). The active site His-460 of human acyl-coenzyme a:cholesterol acyltransferase 1 resides in a hitherto undisclosed transmembrane domain. *J Biol Chem*; 280: 37814-37826
- Helgerud P, Haugen R, Norum KR (1982). The effect of feeding and fasting on the activity of acyl-coa: Cholesterol acyltransferase in rat small intestine. *Eur J Clin Invest*; 12: 493-500
- Hirsch-Reinshagen V, Burgess BL & Wellington CL (2009). Why lipids are important for alzheimer disease? *Mol Cell Biochem*; 326: 121-129

BIBLIOGRAPHY

- Hori M, Miyazaki A, Tamagawa H, et al (2004). Up-regulation of acyl-coenzyme a:cholesterol acyltransferase-1 by transforming growth factor-beta1 during differentiation of human monocytes into macrophages. *Biochem Biophys Res Commun*; 320: 501-505
- Hurthle K (1895). Ueber die fettsäure-cholesterin-ester des blutserums. *Z Physiol Chem*; 21: 332 [Article in German; Referred for Table 1, Section 2]
- Hutter-Paier B, Huttunen HJ, Puglielli L, et al (2004). The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of alzheimer's disease. *Neuron*; 44: 227-238
- Huttunen HJ, Puglielli L, Ellis BC, et al (2009). Novel N-terminal cleavage of APP precludes abeta generation in ACAT-defective AC29 cells. *J Mol Neurosci*; 37: 6-15
- Itabe H, Obama T, Kato R (2011). The dynamics of oxidized ldl during atherogenesis. *J Lipids*; 2011: 418313
- Johnston TP, Palmer WK (1993). Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. *Biochem Pharmacol*; 46: 1037-1042
- Joris I, Zand T, Nunnari JJ, et al (1983). Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. *Am J Pathol*; 113: 341-358
- Joyce C, Skinner K, Anderson RA, et al (1999). Acyl-coenzyme a:cholesteryl acyltransferase 2. *Curr Opin Lipidol*; 10: 89-95
- Joyce CW, Shelness GS, Davis MA, et al (2000). ACAT1 and ACAT2 membrane topology segregates a serine residue essential for activity to opposite sides of the endoplasmic reticulum membrane. *Mol Biol Cell*; 11: 3675-3687
- Junquero D, Bruniquel F, N'Guyen X, et al (2001a). F12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in new zealand rabbits fed a casein-enriched diet. *Atherosclerosis*; 155: 131-142
- Junquero D, Oms P, Carilla-Durand E, et al (2001b). Pharmacological profile of f 12511, (s)-2',3',5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme a: cholesterol acyltransferase inhibitor. *Biochem Pharmacol*; 61: 97-108
- Karuppiah N, Kaufman PB, Kapustka SA, et al (1993). Use of cyclodextrin-cholesterol complex as a primary standard in cholesterol analysis. *Microchem J*; 47: 325-329
- Khelef N, Buton X, Beatini N, et al (1998). Immunolocalization of acyl-coenzyme a:cholesterol o-acyltransferase in macrophages. *J Biol Chem*; 273: 11218-24

BIBLIOGRAPHY

- Kimura T, Takase Y, Hayashi K, et al (1993). Structure-activity relationship of N-[2-(dimethylamino)-6-[3-(5-methyl-4-phenyl-1H-imidazol-1-yl) propoxy] phenyl]-N'-pentylurea and analogs. Novel potent inhibitors of acyl-CoA: cholesterol O-acyltransferase with antiatherosclerotic activity. *J Med Chem*; 36: 1630-1640
- Kinnunen PM, DeMichele A, Lange LG (1988). Chemical modification of acyl-coa:Cholesterol o-acyltransferase. 1. Identification of acyl-coa:cholesterol o-acyltransferase subtypes by differential diethyl pyrocarbonate sensitivity. *Biochemistry*; 27: 7344-7350
- Kritchevsky D (1995). Dietary protein, cholesterol and atherosclerosis: a review of the early history. *J Nutrition*; 125: 589S-593S
- Kumazawa T, Harakawa H, Fukui H, et al (1995). N-(1-phenyl-2-benzimidazolyl)-N'-phenylurea derivatives as potent inhibitors of acyl coa: cholesterol acyltransferase (ACAT). *Bioorg Med Chem Lett*; 5: 1829-1832
- Kupke IR, Zeugner S (1978). Quantitative high-performance thin-layer chromatography of lipids in plasma and liver homogenates after direct application of 0.5- μ l samples to the silica-gel layer. *J Chrom B: Biomed Sci App*; 146: 261-271
- Kusunoki J, Aragane K, Kitamine T, et al (1995). Hypocholesterolemic action and prevention of cholesterol absorption via the gut by f-1394, a potent acyl-coa:Cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed rats. *Jpn J Pharmacol*; 69: 53-60
- Kusunoki J, Hansoty DK, Aragane K, et al (2001). Acyl-CoA: cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. *Circulation*; 103: 2604-2609
- Lada AT, Chapman J, Wu ZD, et al (2003). Unique inhibitory responses of ACAT1 versus ACAT2 based on a novel, cell-based fluorescent ACAT assay. *Arterioscler Thromb Vasc Biol*; 23: A71-A79
- Lada AT, Davis M, Kent C, et al (2004). Identification of ACAT1-and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness. *J Lip Res*; 45: 378-386
- Largis EE, Wang CH, DeVries VG, et al (1989). CL 277,082: a novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. *J Lip Res*; 30: 681-690
- Lee K, Cho SH, Lee JH, et al (2013). Synthesis of a novel series of 2-alkylthio substituted naphthoquinones as potent acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors. *Eur J Med Chem*; 62: 515-525

BIBLIOGRAPHY

- Lee O, Chang CC, Lee W, et al (1998). Immunodepletion experiments suggest that acyl-coenzyme a:Cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. *J Lip Res*; 39: 1722-1727
- Lee RG, Kelley KL, Sawyer JK, et al (2004). Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. *Circ Res*; 95: 998-1004
- Lei L, Xiong Y, Chen J, et al (2009). Tnf-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. *J Lip Res*; 50: 1057-67
- Levy E, Spahis S, Sinnott D, et al (2007). Intestinal cholesterol transport proteins: an update and beyond. *Curr Opin Lipidol*; 18: 310-318
- Li BL, Li XL, Duan ZJ, et al (1999). Human acyl-coa:Cholesterol acyltransferase-1 (ACAT-1) gene organization and evidence that the 4.3-kilobase ACAT-1 mRNA is produced from two different chromosomes. *J Biol Chem*; 274: 11060-71
- Libby P, Aikawa M (2002). Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. *Nat Med*; 8: 1257-62
- Lin S, Cheng D, Liu MS, et al (1999). Human acyl-coa:Cholesterol acyltransferase-1 in the endoplasmic reticulum contains seven transmembrane domains. *J Biol Chem*; 274: 23276-85
- Lin S, Lu X, Chang CC, et al (2003). Human acyl-coenzyme a:cholesterol acyltransferase expressed in chinese hamster ovary cells: Membrane topology and active site location. *Mol Biol Cell*; 14: 2447-2460
- Linton MF, Fazio S (2003). Macrophages, inflammation, and atherosclerosis. *Int J Obes Relat Metab Disord*; 27: S35-S40
- Liu J, Chang C, Westover E, et al (2005). Investigating the allostereism of acyl-CoA: cholesterol acyltransferase (ACAT) by using various sterols: in vitro and intact cell studies. *Biochem J*; 391: 389-397
- Llaverías G, Laguna JC, Alegret M (2003). Pharmacology of the ACAT Inhibitor Avasimibe (CI-1011). *Cardiovasc Drug Rev*; 21: 33-50
- Maechler P, Wollheim CB, Bentzen CL, et al (1992). Role of the intestinal acyl-CoA: cholesterol acyltransferase activity in the hyperresponse of diabetic rats to dietary cholesterol. *J Lip Res*; 33: 1475-1484

BIBLIOGRAPHY

- Matsuda H, Hakamata H, Miyazaki A, et al (1996). Activation of acyl-coenzyme a:cholesterol acyltransferase activity by cholesterol is not due to altered mRNA levels in HepG2 cells. *Biochim Biophys Acta*; 1301: 76-84
- Matsumura T, Kugiyama K, Sugiyama S, et al (1999). Suppression of atherosclerotic development in Watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast. *Circulation*; 99: 919-924
- Matsuzawa N, Takamura T, Kurita S, et al (2007). Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. *Hepatology*; 46: 1392-1403
- Maulik M, Westaway D, Jhamandas JH, et al (2013). Role of cholesterol in APP metabolism and its significance in alzheimer's disease pathogenesis. *Mol Neurobiol*; 47: 37-63
- Meiner VL, Cases S, Myers HM, et al (1996). Disruption of the acyl-coa:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. *PNAS USA*; 93: 14041-14046
- Meiner V, Tam C, Gunn MD, et al (1997). Tissue expression studies on the mouse acyl-coa: cholesterol acyltransferase gene (*acact*): findings supporting the existence of multiple cholesterol esterification enzymes in mice. *J Lipid Res*; 38: 1928-1933
- Meuwese MC, de Groot E, Duivenvoorden R, et al (2009). ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: The captivate randomized trial. *JAMA*; 301: 1131-1139
- Millar JS, Cromley DA, McCoy MG, et al (2005). Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. *J Lip Res*; 46: 2023-2028
- Miyazaki A, Sakashita N, Lee O, et al (1998). Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. *Arterioscler Thromb Vasc Biol*; 18: 1568-1574
- Miyoshi N, Iwasaki N, Tomono S, et al (2013). Occurrence of cytotoxic 9-oxononanoyl secosterol aldehydes in human low-density lipoprotein. *Free Radical Biol Med*; 60: 73-79
- Mizoguchi T, Edano T, Koshi T (2004). A method of direct measurement for the enzymatic determination of cholesteryl esters. *J Lip Res*; 45: 396-401
- Mukherjee S, Kunitake G, Alfinlater RB (1958). The esterification of cholesterol with palmitic acid by rat liver homogenates. *J Biol Chem*; 230: 91-96

BIBLIOGRAPHY

- Musanti R, Giorgini L, Lovisolo P, et al (1996). Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. *J Lip Res*; 37: 1-14
- Namatame I, Tomoda H, Ishibashi S, et al (2004). Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages. *PNAS USA*; 101: 737-742
- Natori K, Okazaki Y, Nakajima T, et al (1986). Mechanism of the inhibition of cholesterol absorption by DL-melinamide: inhibition of cholesterol esterification. *Jpn J Pharmacol*; 42: 517-523
- Nguyen TM, Sawyer JK, Kelley KL, et al (2012). Cholesterol esterification by ACAT2 is essential for efficient intestinal cholesterol absorption: Evidence from thoracic lymph duct cannulation. *J Lip Res*; 53: 95-104
- Nishina PM, Verstuyft J, Paigen B (1990). Synthetic low and high fat diets for the study of atherosclerosis in the mouse. *J Lip Res*; 31: 859-869
- Nissen SE, Tuzcu EM, Brewer HB, et al (2006). Effect of ACAT inhibition on the progression of coronary atherosclerosis. *N Engl J Med*; 354: 1253-1263
- Oelkers P, Behari A, Cromley D, et al (1998). Characterization of two human genes encoding acyl coenzyme a:cholesterol acyltransferase-related enzymes. *J Biol Chem*; 273: 26765-26771
- Ohnuma S, Muraoka M, Ioriya K, et al (2004). Synthesis and structure-activity relationship studies on a novel series of naphthylidinyureas as inhibitors of acyl-CoA: cholesterol-O-acyltransferase (ACAT). *Bioorg Med Chem Lett*; 14: 1309-1311
- Ohshiro T, Matsuda D, Sakai K, et al (2011). Pyripyropene A, an acyl-coenzyme a: cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. *Arterioscler Thromb Vasc Biol*; 31: 1108-1115
- Ohtawa M, Yamazaki H, Ohte S, et al (2013a). Synthesis and structure-activity relationship of pyripyropene a derivatives as potent and selective acyl-coa:Cholesterol acyltransferase 2 (ACAT2) inhibitors: Part 1. *Bioorg Med Chem Lett*; 23: 1285-7
- Ohtawa M, Yamazaki H, Matsuda D, et al (2013b). Synthesis and structure-activity relationship of pyripyropene a derivatives as potent and selective acyl-coa:Cholesterol acyltransferase 2 (ACAT2) inhibitors: Part 2. *Bioorg Med Chem Lett*; 23: 2659-62
- Ouimet M & Marcel YL (2012). Regulation of lipid droplet cholesterol efflux from macrophage foam cells. *Arterioscler Thromb Vasc Biol*; 32: 575-581

BIBLIOGRAPHY

- Pal P, Gandhi H, Giridhar R, et al (2012). ACAT inhibitors: The search for novel cholesterol lowering agents. *Mini Rev Med Chem*; 13: 1195-1219
- Pape ME, Schultz PA, Rea TJ, et al (1995). Tissue specific changes in acyl-coa: Cholesterol acyltransferase (ACAT) mrna levels in rabbits. *J Lipid Res*; 36: 823-838
- Puglielli L, Konopka G, Pack-Chung F, et al (2001). Acyl-coenzyme a: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. *Nat Cell Biol*; 3: 905-912
- Puglielli L, Tanzi RE, Kovacs DM (2003). Alzheimer's disease: The cholesterol connection. *Nat Neurosci*; 6: 345-351
- Reindel JF, Dominick MA, Bocan TM, et al (1994). Toxicologic effects of a novel acyl-CoA: cholesterol acyltransferase inhibitor in cynomolgus monkeys. *Toxicol Pathol*; 22: 510-518
- Rival Y, Junquero D, Bruniquel F, et al (2002). Anti-atherosclerotic properties of the acyl-coenzyme a:cholesterol acyltransferase inhibitor F12511 in casein-fed new zealand rabbits. *J Cardiovasc Pharmacol*; 39: 181-191
- Rong JX, Blachford C, Feig JE, et al (2013). ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. *Arterioscler Thromb Vasc Biol*; 33: 4-12
- Rong JX, Kusunoki J, Oelkers P, et al (2005). Acyl-coenzyme a (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation. *Arterioscler Thromb Vasc Biol*; 25: 122-127
- Ross R (1999). Atherosclerosis--an inflammatory disease. *N Engl J Med*; 340: 115-126
- Roth BD (1998). ACAT inhibitors: evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents. *Drug Discov Today*; 3: 19-25
- Sakashita N, Chang CC, Lei X, et al (2010). Cholesterol loading in macrophages stimulates formation of er-derived vesicles with elevated ACAT1 activity. *J Lipid Res*; 51: 1263-72
- Sakashita N, Miyazaki A, Takeya M, et al (2000). Localization of human acyl-coenzyme a: cholesterol acyltransferase-I (ACAT-1) in macrophages and in various tissues. *Am J Pathol*; 156: 227-236
- Seo T, Oelkers PM, Giattina MR, et al (2001). Differential modulation of ACAT1 and ACAT2 transcription and activity by long chain free fatty acids in cultured cells. *Biochemistry*; 40: 4756-4762
- Shelness GS, Sellers JA (2001). Very-low-density lipoprotein assembly and secretion. *Curr Opin Lipidol*; 12: 151-157

BIBLIOGRAPHY

- Shobab LA, Hsiung GY, Feldman HH (2005). Cholesterol in alzheimer's disease. *Lancet Neurol*; 4: 841-852
- Smith JL, Rangaraj K, Simpson R, et al (2004). Quantitative analysis of the expression of ACAT genes in human tissues by real-time pcr. *J Lip Res*; 45: 686-696
- Song BL, Wang CH, Yao XM, et al (2006). Human acyl-coa:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma. *Biochem J*; 394: 617-626
- Sorci-Thomas MG, Thomas MJ (2012). High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. *Arterioscler Thromb Vasc Biol*; 32: 2561-2565
- Spector AA, Haynes WG (2007). LDL cholesteryl oleate a biomarker for atherosclerosis? *Arterioscler Thromb Vasc Biol*; 27: 1228-1230
- Sperry WM (1935). Cholesterol esterase in blood. *J Biol Chem*; 111: 467-478
- Tabas I (2002). Consequences of cellular cholesterol accumulation: Basic concepts and physiological implications. *J Clin Invest*; 110: 905-911
- Tailford KA, Berry CL, Thomas AC, et al (2003). A casein variant in cow's milk is atherogenic. *Atherosclerosis*; 170: 13-19
- Tardif JC, Gregoire J, L'Allier PL, et al (2004). Effects of the acyl coenzyme a:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. *Circulation*; 110: 3372-3377
- Tawada H, Harcourt M, Kawamura N, et al (1994). Novel acyl-CoA: cholesterol acyltransferase inhibitors. Synthesis and biological activity of 3-quinolylurea derivatives. *J Med Chem*; 37: 2079-2084
- Temel RE, Gebre AK, Parks JS, et al (2003). Compared with acyl-coa:cholesterol o-acyltransferase (ACAT) 1 and lecithin:cholesterol acyltransferase, ACAT2 displays the greatest capacity to differentiate cholesterol from sitosterol. *J Biol Chem*; 278: 47594-47601
- Temel RE, Hou L, Rudel LL, et al (2007). ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins. *J Lip Res*; 48: 1618-1627
- Tomoda H, Huang XH, Cao J, et al (1992). Inhibition of acyl-CoA: cholesterol acyltransferase activity by cyclodepsipeptide antibiotics. *J Antibiotics*; 45: 1626-1632
- Touchstone JC (1995). Thin-layer chromatographic procedures for lipid separation. *J Chrom B: Biomed Sci App*; 671: 169-195

BIBLIOGRAPHY

- Trivedi BK, Holmes A, Purchase TS, et al (1995). A series of conformationally and sterically constrained analogs of N-phenyl-N'-aralkylurea ACAT inhibitors. *Bioorg Med Chem Lett*; 5: 2229-2234
- Uchida T, Aoyama K, Watanabe T, et al (1998). Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats. *Atherosclerosis*; 137: 97-106
- Uelmen PJ, Oka K, Sullivan M, et al (1995). Tissue-specific expression and cholesterol regulation of acylcoenzyme a:Cholesterol acyltransferase (ACAT) in mice. Molecular cloning of mouse ACAT cDNA, chromosomal localization, and regulation of ACAT in vivo and in vitro. *J Biol Chem*; 270: 26192-26201
- Vassiliadis E, Barascuk N, Karsdal MA (2013). Atherofibrosis - a unique and common process of the disease pathogenesis of atherosclerosis and fibrosis - lessons for biomarker development. *Am J Transl Res*; 5: 1-14
- Vergnes L, Phan J, Strauss M, et al (2003). Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. *J Biol Chem*; 278: 42774-42784
- Voloshyna I, Reiss AB (2011). The ABC transporters in lipid flux and atherosclerosis. *Prog Lipid Res*; 50: 213-224
- Wang H, Germain SJ, Benfield PP, et al (1996). Gene expression of acyl-coenzyme-a:Cholesterol-acyltransferase is upregulated in human monocytes during differentiation and foam cell formation. *Arterioscler Thromb Vasc Biol*; 16: 809-814
- Webb NR, Moore KJ (2007). Macrophage-derived foam cells in atherosclerosis: lessons from murine models and implications for therapy. *Curr Drug Targets*; 8: 1249-1263
- Westover EJ, Covey DF (2004). The enantiomer of cholesterol. *J Membr Biol*; 202: 61-72
- White AD, Creswell MW, Chucholowski AW, et al (1996). Heterocyclic ureas: inhibitors of acyl-coa: cholesterol o-acyltransferase as hypocholesterolemic agents. *J Med Chem*; 39: 4382-4395
- Windaus AU (1910). Uber den gehalt normaler und atheromatoser aorten an cholesterin und cholesterinestern. *Hoppe-Seyler's Z Physiol Chem*; 67: 174-176 [Article in German; Referred for Table 1, Section 2]
- Wollmer MA, Streffer JR, Tsolaki M, et al (2003). Genetic association of acyl-coenzyme a: Cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for alzheimer's disease. *Mol Psychiatry*; 8: 635-638

BIBLIOGRAPHY

- Yagyu H, Kitamine T, Osuga J, et al (2000). Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. *J Biol Chem*; 275: 21324-21330
- Yagyu H, Kitamine T, Osuga JI, et al (2000). Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. *J Biol Chem*; 275: 21324-21330
- Yang H, Cromley D, Wang H, et al (1997). Functional expression of a cDNA to human acyl-coenzyme a:cholesterol acyltransferase in yeast. Species-dependent substrate specificity and inhibitor sensitivity. *J Biol Chem*; 272: 3980-3985
- Yang JB, Duan ZJ, Yao W, et al (2001). Synergistic transcriptional activation of human acyl-coenzyme a: cholesterol acyltransferase-1 gene by interferon-gamma and all-trans-retinoic acid THP-1 cells. *J Biol Chem*; 276: 20989-20998
- Yang L, Yang JB, Chen J, et al (2004). Enhancement of human ACAT1 gene expression to promote the macrophage-derived foam cell formation by dexamethasone. *Cell Res*; 14: 315-323
- Yu C, Chen J, Lin S, et al (1999). Human acyl-coa:Cholesterol acyltransferase-1 is a homotetrameric enzyme in intact cells and in vitro. *J Biol Chem*; 274: 36139-36145
- Yu C, Zhang Y, Lu X, et al (2002). Role of the n-terminal hydrophilic domain of acyl-coenzyme a:cholesterol acyltransferase 1 on the enzyme's quaternary structure and catalytic efficiency. *Biochemistry*; 41: 3762-3769
- Zhang J, Kelley KL, Marshall SM, et al (2012). Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood. *J Lip Res*; 53: 1144-1152
- Zhang Y, Da Silva JR, Reilly M, et al (2005). Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. *J Clin Invest*; 115: 2870-2874
- Zhang Y, Yu C, Liu J, et al (2003). Cholesterol is superior to 7-ketocholesterol or 7 alpha-hydroxycholesterol as an allosteric activator for acyl-coenzyme a:cholesterol acyltransferase 1. *J Biol Chem*; 278: 11642-11647